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ABSTRACT
Host-virus systems biology seeks to elucidate the complex interactions between a virus and
its host, and to determine the downstream consequences of these interactions for the host.
Traditional studies of host-virus interactions, conducted one-at-a-time, yield high-quality
results, but these have limited scope. By contrast, systems biology uses a holistic approach
to examine many interactions simultaneously, thereby increasing the breadth of interactions
revealed. However, these studies have largely focused on common human pathogens (e.g.,
influenza or HIV), and their results may not apply to unrelated viruses, such as those that
cause hemorrhagic fevers. Combining experimental and computational techniques can
yield novel information about host-virus interactions that traditional virological or purely
computational systems-biology methods cannot uncover. In this thesis, I demonstrate the
utility of combined experimental and computational approaches by: (1) revealing general
principles of host-virus interactions, broadly applicable to a wide range of viruses; and (2)
probing a specific host-virus interaction system to identify transcriptional signatures which
elucidate host response to Ebola virus.
I identify general mechanisms governing host-virus protein-protein interactions (PPIs)
v
using domain-resolved PPI networks. This method identifies mechanistic differences be-
tween virus-human and within-human interactions, such as the preference viral proteins
exhibit for binding human proteins containing linear motif-binding domains. Using domain-
resolved PPIs reveals novel signatures of pleiotropy, economy, and convergent evolution in
the viral-host interactome not previously identified in other PPI networks.
I further identify transcriptional signatures of host response to Ebola virus (EBOV)
infection by pairing high-throughput microarray data with advanced pathway analyses. I
compare EBOV-infected, non-human primates with and without anticoagulant treatment,
to identify transcriptional signatures associated with survival following infection. Having
found that CCAAT-enhancer binding proteins (CEBPs) are associated with survival, I
determine the role CEBPs have in EBOV infection by using comparative microarray anal-
ysis of multiple viral infections of hemorrhagic and non-hemorrhagic origin. I also identify
unique transcriptional changes in the host that distinguish EBOV infection from other viral
infections, such as Influenza.
Integrating these two areas of research provides information about universally applica-
ble patterns of viral infection, while simultaneously examining the consequences of specific
host-pathogen interactions.
vi
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1Chapter 1
Introduction
1.1 Host-virus protein-protein interaction networks
Protein-protein interactions (PPIs) occur when two or more proteins physically bind to-
gether in order to coordinately perform a molecular function, such as catalyzing a re-
action, regulating transcription of genes, or providing scaffolding for cellular structure.
These PPIs can be broadly classified as either (1) stable interactions, in which proteins
form multi-subunit complexes, e.g. RNA polymerase [100]; or (2) transient interactions, in
which proteins temporarily bind to perform a molecular function, e.g. the case of a kinase
temporarily binding and phosphorylating another protein [141]. Interactions are typically
thought of as occurring between proteins within one organism, and are called endogenous
interactions; however, PPIs can also occur between the proteins of different organisms, such
as between a parasitic microorganism and its host. These types of interactions, especially
in the context of host-pathogen studies, are called exogenous interactions. A PPI network,
or interactome, is the collection of all interactions occurring amongst the proteins of one
organism, or between the proteins of a pathogen and its host.
Of particular interest are PPIs that occur between a virus and its host organism
[20, 39, 40, 41, 73, 125, 135, 164, 181, 188, 194]. Viruses are obligate intracellular par-
asites with extremely small genomes and proteomes; therefore, their ability to replicate
is wholly dependent on interactions with its host [50]. A common example of host-virus
interactions is the binding of a viral glycoprotein to a host cell surface receptor, for entry
of the virus into the host cell. However, more complex interactions can also exist. For
example, although several viruses may encode a viral RNA or DNA polymerase in order
to perpetuate its genome, all viruses require the host ribosomal machinery in order to
translate their genome into a proteome [117, 197]. Many viruses use host cell machinery
2to package and transport viral products, and hijack host macromolecular complexes such
as the bilipid cellular membrane in order to create virions [106]. Physical binding between
viral proteins and host proteins creates competition for endogenous interactions [51], and
host-virus PPIs can alter the function or structure of host proteins [24, 120, 128]. Finally,
viruses are known to modulate host immune responses within cells and extracellular spaces,
in order to inhibit immune activity of the host [4, 14, 49]. Consequently, viral proteins
must be able to bind to and manipulate host cell machinery.
Previous studies of host-virus PPI networks have found that viral proteins tend to
bind and interact with human proteins that are important to the human interactome
[20, 33, 40, 144]. Some of the human targets of viral proteins are hub proteins, which interact
with many other proteins [5, 123]. Other human proteins are bottleneck proteins, which may
participate in fewer interactions than hub proteins, but are central to a specific pathway in
the human interactome due to their importance in pathways [209]. Hypothetically, a viral
protein targeting these two categories of human proteins will maximally disrupt the normal
function of the human interactome, by interrupting the normal functioning of important
proteins. Viral proteins employ specific strategies to maximize the effectiveness of host-
virus PPIs [144]. The physical interaction between two proteins can be mediated in one
of two ways: (1) the globular domain of one protein binding to the globular domain of
another protein (domain-domain interaction; DDI); or, (2) a short linear peptide motif
in one protein binding the globular domain in another protein (domain-motif interaction;
DMI). Typically, DDIs are considered to produce more stable interactions, whereas DMIs
are thought to be indicative of transient interactions, although some DDIs mediate transient
interactions, as well.
However, the question of which mechanisms viral proteins preferentially use to interact
with human proteins remains to be answered [53]. Previous research has demonstrated the
utility of combining three-dimensional structural models of proteins with PPI networks
[51], and this process can be used to elucidate the mechanisms by which viral proteins
interact with host proteins. For example, previous research has shown that viral proteins
3preferentially bind to endogenous protein interfaces which are transient and regulatory in
function. However, the coverage of high-resolution interactome networks is limited by the
number of available 3D structures of viral and human PPIs [52]. In contrast, the typical
systems biology approach which utilizes low-resolution binary PPIs has broad coverage, but
has limited ability to elucidate the mechanisms of interaction (e.g. DDIs and DMIs), due
to the fact that these approaches treat proteins as nodes and physical interactions as edges.
Therefore, to identify how viral proteins target human proteins, and how these interactions
differ from normal human-human PPIs, I developed a high-resolution, broadly-applicable
approach to investigating host-virus interaction systems.
In Chapter 2, I used a high-resolution human-virus PPI network to examine the underly-
ing principles which govern host-virus interactions, and to compare them to the mechanisms
governing within-host interactions. I annotated individual proteins with known domain in-
formation using sequence analysis, which allows a more high resolution approximation of
the mechanism of interaction, when compared to traditional PPI networks. I annotated
PPIs by evaluating whether the interacting proteins contain domains known to interact
with one another. This additional step provides a high resolution view of the mechanism
of interaction, i.e. whether the interaction is domain-domain interaction, or whether it is a
domain-motif interaction. The resulting PPI network is of higher resolution than a typical
binary PPI network, which provides no information about the mechanism of interaction,
and has broader coverage than a 3D structural interaction network, which is limited in size
due to lack of available structures. In this work, I completed a systematic, quantitative,
and global study of the human-virus interaction network, compared to the human-human
interaction network. I determined that viral proteins use interaction mechanisms to target
human proteins that are statistically significantly different from the interaction mechanisms
that are typically used in within-human interactions, e.g. viral proteins are more likely to
target human proteins containing linear motif-binding domains, than human proteins are.
Finally, I identified novel trends which suggest that viral proteins employ specific strategies
for maximizing the effectiveness of their interactions with human proteins.
41.2 Host transcriptional response to Ebolavirus
There are five Ebolavirus species in the family Filoviridae, a group of negative-sense single-
stranded RNA viruses [44], which have varying morbidity and mortality rates. Some
Ebolaviruses such as Reston (RESTV) and Ta¨ı Forest (TAFV) have no human fatali-
ties reported, whereas other Ebolaviruses have extremely high average case fatality rates:
Bundibugyo (BDBV; 34%), Sudan (SUDV; 54%) and Zaire (EBOV; 78%) [203]. Infec-
tions and outbreaks occur predominantly in Sub-Saharan Africa. Infection of humans and
non-human primates by EBOV leads to Ebola Virus Disease (EVD), a severe acute viral
infection which can lead to viral hemorrhagic fever [44, 82, 85]. Infection primarily oc-
curs through direct contact with blood or bodily fluids from an infected host, although it
has been established that infection can occur via the aerosol route [142]. Primary cellu-
lar targets of infection include hepatocytes and some peripheral blood mononuclear cells
(PBMCs), such as monocytes, macrophages, and dendritic cells [17, 18, 44, 56, 57, 150].
Infected immune cells release pro-inflammatory chemokines and cytokines such as ERK1/2,
IL-2, IL-10, NF-κB and TNFα [74, 81, 122, 126, 158, 192, 208, 211]. Virus-induced cir-
culating cytokines can increase permeability of endothelial cells [45]; this increased per-
meability, coupled with the lytic effect of EBOV virion budding, may decrease vascular
integrity [196, 207]. Hypercoagulation can cause additional intravascular damage, which in
turn can lead to coagulopathy, a condition in which the blood loses the ability to coagulate.
Thrombocytopenia, which is a decrease of platelets in the serum, is also observed during
EVD and can inhibit normal clotting [162].
The incubation period of Ebolavirus is roughly 3 weeks, with symptoms occurring be-
tween 2 days and 2 weeks post-infection [44, 50]. Early clinical symptoms of EVD are
flu-like in nature, and include fever, joint and muscle pain, weakness and fatigue, sore
throat or coughing, headache, and gastrointestinal symptoms such as nausea, vomiting,
diarrhea [44]. These early-stage symptoms of EBOV can be clinically indistinguishable
from other infections, such as influenza, during early stages of infection. As infection pro-
5gresses, cutaneous symptoms such as maculopapular rash and hematomas may present,
which can be indicative of coagulopathies [46]. EBOV infection leads to a decrease of func-
tional macrophages and dendritic cells, impairing the host immune response [18]. In the
liver, infected hepatocytes can become necrotic, possibly leading to the production of dys-
functional clotting factors [187]. Late-stage symptoms include disseminated intravascular
coagulopathy (DIC), multiple organ failure, hypotension, sepsis, and coma [126, 187, 208].
Late-stage symptoms can be confused with other illness prevalent in regions with EBOV,
such as malaria, bacterial sepsis, and other viral hemorrhagic fevers such as those caused
by infection of Marburgvirus (Filoviridae) or Lassavirus (Arenaviridae). A critical goal
in Ebolavirus research is to identify biomarkers of EBOV infection which can differenti-
ate infection with EBOV from other viral infections, and to identify indicators of disease
outcome and survival.
To date, there are no FDA-approved post-exposure treatments for human use, although
numerous candidate therapeutics have been evaluated. In the realm of pre-exposure ther-
apy, several vaccines have been created using recombinant viral vectors, such as recombi-
nant Adenovirus [152, 178], and recombinant Vesicular Stomatitis Virus [47, 58, 59, 92].
These vaccines can protect NHPs from EBOV infection when administered prior to expo-
sure [58, 59, 92, 178]; in the case of VSV-based vectors, vaccination also protects NHPs
from EBOV infection when administered after exposure to EBOV [47]. Several advanced-
stage vaccines are able to protect NHPs against different species of Ebolavirus, and Mar-
burgvirus, which is a related Filovirus that can cause similar symptoms [58, 59, 92]. Several
other post-exposure therapeutics are also in development. It has been shown that small
interfering RNAs (siRNAs), developed against the Ebolavirus viral RNA polymerase, can
protect NHPs from EBOV infection when administered after viral challenge [60]. In addi-
tion, previous research has demonstrated that anticoagulant therapeutics can mitigate the
pathologies of EBOV infection in NHPs [55, 83]. Treatment with drugs such as recombi-
nant nematode anticoagulant protein c2 (rNAPc2) [55], or recombinant human activated
protein C (rhAPC) [83] can result in a 33% survival rate of an otherwise 100% lethal EBOV
6infection. In addition, it was recently shown that a novel nucleoside analogue, BCX4430,
protects NHPs against EBOV infection [203].
Although numerous studies have identified therapeutics which can protect NHPs from
EBOV infection, there is still a great deal that is unknown about the general pathogenesis of
EBOV infection. Studies have only peripherally described how EBOV infection affects the
host immune response, and many questions remain regarding the pathogenesis of EBOV. In
general, studies of EBOV infection described the disease progression using clinical symp-
toms of infection, or by using individual gene and protein assays to evaluate the host
response to infection. To understand the underlying changes in the host that occur during
EVD, it is necessary to utilize a more comprehensive approach to studying the immune
response during infection. Recently, several studies have used high-throughput methods,
such as microarray analysis, to study the global transcriptome of the host in response to
infection. Several early approaches have applied high-throughput microarray studies to
characterize the host immune response to EBOV infection in NHPs [158, 208]. A study ex-
amining the peripheral blood mononuclear cells (PBMCs) of EBOV-infected NHPs showed
that infection triggers up-regulation of pro-inflammatory markers such as chemokines, cy-
tokines, interleukins, interferon-inducible proteins, Toll-like receptor signaling (TLR), and
TNFα [158]. Microarray analysis has shown that infection is characterized by dysregula-
tion of genes associated with apoptosis, destruction of lymphocytes, acute phase response,
and coagulation. Additional microarray studies analyzing host immune response to EBOV
infection following anticoagulant treatment, have demonstrated that anticoagulants drasti-
cally change the transcriptome of the host [208]. In particular, anticoagulant therapeutics
mitigate the extreme dysregulation that occurs in the host in response to EBOV infection.
For example, up-regulation of pro-inflammatory markers was less severe in anticoagulant-
treated NHPs, as opposed to NHPs which did not receive treatment [208]. In addition,
studies utilizing microarrays have demonstrated that significant changes occur in the host
immune transcriptome as early as 3 days post-infection, prior to the appearance of clinical
symptoms [158]. This suggests that transcriptomic analysis reveals unique changes in the
7host that are otherwise unobserved in a clinical setting, illustrating the utility of using
microarray analysis to identify biomarkers of EBOV infection.
Current transcriptomic studies evaluating the host response to EBOV infection have
looked for global patterns of immune response and successful disease mitigation [158, 208].
However, to date, a thorough investigation of transcriptional signatures correlated with
survival has not been completed. Previous studies which have identified correlates of
survival have been limited in scope to individual gene or protein assays [126]. There
is a need for a probing analysis to uncover unique signatures associated with survival,
which goes beyond simple microarray analysis. Typical analysis of microarrays involves
looking for changes in gene expression between time-points, or between disease states,
looking for specific genes or groups of genes; however, these studies frequently overlook
the sources of these transcriptional changes. The use of pathway and network analysis can
aid in identifying upstream regulators of transcriptional changes, which would otherwise
be missed in typical microarray analysis. Furthermore, transcriptional analysis can be
used to differentiate EBOV infection from other viral infections, including those that cause
hemorrhagic fever. However, simply differentiating between viral infections is not enough:
in order to understand how the host uniquely responds to different viral infections, it is
necessary to understand why specific genes may become differentially regulated.
In Chapter 3, I used high-throughput complementary DNA (cDNA) microarrays to as-
sess the host immune response of anticoagulant-treated NHPs infected with EBOV. I com-
pared animals that survive EBOV challenge due to anticoagulant treatment, to animals that
do not survive, regardless of whether treatment was administered. I did not differentiate
between treatments applied, as in previous studies [208], but instead focused on identi-
fying transcriptional correlates of survival. In addition, I was interested in determining
the biological meaning behind the transcriptional signatures I observed. I used functional
annotation to group genes into functional categories, and pathway analysis software to iden-
tify up-stream transcriptional regulators (IPA; Ingenuity R©Systems, www.ingenuity.com).
I identified sets of genes functionally controlled by common transcription factors, and used
8networks to illustrate connections between genes. I evaluated the ability of these gene
sets to distinguish survivors from non-survivors using hierarchical clustering, leave-one-out
cross-validation, receiving operator characteristic (ROC) curves, and additional experimen-
tal validation such as RT-PCR. In this work, I completed a quantitative transcriptomic
comparison of surviving and non-surviving NHPs infected with EBOV. I identified two
sets of genes which are capable of statistically distinguishing between survivors and non-
survivors: (1) a minimal set of 20 genes which are capable of separating survivors from
non-survivors; and (2) a larger transcriptional signature of 238 genes which is characterized
by functionally related sub-networks of genes. Using pathway and network analysis, I iden-
tified novel transcriptional regulators which are correlated with survival, and which have
not been previously associated with Ebolavirus infection. For example, using a compara-
tive analysis of survivors and non-survivors, I identified CEBPA as a transcription factor
correlated with survival.
In Chapter 4, I extended my previous findings to other viral hemorrhagic fevers, such as
the related Marburgvirus. In particular, I focused on determining the role that a family of
transcription factors, CCAAT-enhancer-binding proteins (CEBPs), may play in Filovirus
infection. I also determined how regulation of these transcription factors may differ in other
viral infections, such as other viral hemorrhagic fevers like Lassavirus or Denguevirus, or
general non-hemorrhagic infections such as Influenzavirus. I used high-throughput cDNA
microarrays to assess the host immune response to different viral infections, obtaining the
datasets from previously published sources. To determine whether these diverse datasets
are comparable, I used gene sets of house-keeping genes and interferon-regulated genes
as positive controls. I used independent datasets to identify genes which are significantly
differentially regulated in response to CEBP activity, and to determine the downstream
consequences of CEBP up-regulation. In this work, I completed a quantitative, compara-
tive analysis of several microarray datasets to identify the regulation of CEBPs following
Filovirus infection, and to contrast this regulation with other viral infections. I determined
that the transcription of CEBPs is uniquely up-regulated in Filovirus infection, and that
9this up-regulation leads to subsequent dysregulation of down-stream genes transcription-
ally regulated by CEBPs. I determined that this signature is uniquely associated with the
CEBP pathway, and is not a byproduct of acute phase response. I also identified a putative
role of CEBPs in Filovirus which may be indicative of dysregulation of iron metabolism,
and which may be associated with low-density granulocyte activity.
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Chapter 2
Signatures of Pleiotropy, Economy and Convergent Evolution in a
Domain-Resolved Map of Human-Virus Protein-Protein Interaction
Networks
2.1 Abstract
A central challenge in host-pathogen systems biology is the elucidation of general, systems-
level principles that distinguish host-pathogen interactions from within-host interactions.
Current analyses of host-pathogen and within-host protein-protein interaction networks
are largely limited by their resolution, treating proteins as nodes and interactions as edges.
Here, I construct a domain-resolved map of human-virus and within-human protein-protein
interaction networks by annotating protein interactions with high-coverage, high-accuracy,
domain-centric interaction mechanisms: (1) domain-domain interactions, in which a do-
main in one protein binds to a domain in a second protein; and (2) domain-motif interac-
tions, in which a domain in one protein binds to a short, linear peptide motif in a second
protein. Analysis of these domain-resolved networks reveals, for the first time, significant
mechanistic differences between virus-human and within-human interactions at the resolu-
tion of single domains. While human proteins tend to compete with each other for domain
binding sites by means of sequence similarity, viral proteins tend to compete with human
proteins for domain binding sites in the absence of sequence similarity. Independent of their
previously established preference for targeting human protein hubs, viral proteins also pref-
erentially target human proteins containing linear motif-binding domains. Compared to
human proteins, viral proteins participate in more domain-motif interactions, target more
unique linear motif-binding domains per residue, and contain more unique linear motifs
per residue. Together, these results suggest that viruses surmount genome size constraints
by convergently evolving multiple short linear motifs in order to effectively mimic, hijack,
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and manipulate complex host processes for their survival. These domain-resolved analy-
ses reveal unique signatures of pleiotropy, economy, and convergent evolution in viral-host
interactions that are otherwise hidden in the traditional binary network, highlighting the
power and necessity of high-resolution approaches in host-pathogen systems biology.
2.2 Introduction
Protein-protein interactions (PPIs) can be broadly classified into two fundamentally dif-
ferent classes: those within the same species, such as within-host PPIs, and those between
different species, such as host-pathogen PPIs. Are there general, systems-level princi-
ples that distinguish host-pathogen PPIs (exogenous interactions) from within-host PPIs
(endogenous interactions)? Surprisingly, little is known about the existence and nature of
such global principles, in part because they are not amenable to investigation by traditional
methods, which examine specific host-pathogen PPIs individually. The most well-studied
host-pathogen interaction systems are host-virus interactions, and the combined results
of decades of detailed studies on specific host-virus interactions suggest that such global
principles may exist. Endogenous interactions among host proteins are expected to be co-
operative: proteins encoded within the same genome interact with one another to carry out
biological function in a coordinated and synergistic fashion. On the contrary, exogenous
interactions between viral proteins and host proteins are expected to be largely antago-
nistic: viruses physically manipulate host cell machinery to perpetuate their genomes at
the host’s expense. In addition to hijacking host macromolecular complexes to make new
viral products, viruses are known to modulate the host response to infection in order to
escape detection and prevent the host from interfering with viral replication [4, 14, 49].
Many viral proteins directly compete with host proteins for binding sites [51], and some
even modify host proteins chemically, e.g. marking them for degradation by the host’s own
machinery [24, 120, 128]. Despite providing such detailed information about the molec-
ular mechanisms and consequences of specific exogenous interactions, traditional virology
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studies are highly focused and thus are often unable to draw general conclusions about
the mechanisms governing exogenous interactions even among closely related viruses. As a
result, despite these detailed studies on specific host-virus interaction systems, the overar-
ching principles that distinguish host-virus interactions from within-host interactions have
not yet been elucidated.
A systems biology approach is therefore essential in order to obtain a global perspec-
tive on host-pathogen interactions. Recent advances in high-throughput experimental and
computational biology have enabled the reconstruction and analysis of large-scale host-
pathogen PPI networks [20, 39, 40, 41, 73, 125, 135, 164, 181, 188, 194]. These systematic
studies have successfully revealed global patterns in host-pathogen systems that are oth-
erwise inaccessible by the traditional reductionist approach, which studies host-pathogen
PPIs one at a time. For example, global analyses have revealed that viral proteins have
repeatedly evolved to target host proteins central to the host PPI network (e.g. hubs with
many physical interaction partners) [20, 33, 40]. In addition to targeting common host
pathways regulating viral infection and replication in general [40, 144], different classes of
viruses also target host pathways uniquely involved in class-specific mechanisms of infec-
tion and replication [144]. Despite these advances, current host-pathogen systems biology
approaches are highly abstract and coarse-grained, treating proteins as nodes and PPIs as
edges; therefore, the insights generated by these analyses are strongly limited in spatial
and mechanistic resolution. A high-resolution approach is needed to uncover more general
rules governing host-pathogen PPI networks [53].
One approach to increase resolution in PPI networks has been to construct three-
dimensional (3D) structural models to protein interactions [102, 132, 167, 201]. This tech-
nique was recently used to build an atomic-resolution map of human-virus and within-
human PPI networks by constructing 3D structural models of exogenous and endogenous
PPIs using homology modeling [51]. A direct comparison between the resulting human-
virus and within-human structural interaction networks revealed systematic and significant
differences between exogenous and endogenous interactions that are otherwise hidden in
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the binary PPI networks. For example, viral proteins preferentially bind to and mimic ex-
isting endogenous interfaces on their human target proteins, rather than creating entirely
new interfaces. In addition, interface mimicry tends to be achieved without structural
similarity in the human-virus PPI network as compared to the within-human PPI net-
work. Finally, endogenous interfaces mimicked by virus proteins tend to evolve quickly,
and mediate many endogenous interactions that are transient and regulatory in function,
as compared to generic endogenous interfaces [51]. Although 3D structure information can
be used to interrogate host-pathogen interaction networks at atomic resolution in a reason-
ably unbiased manner, coverage in these analyses is limited by the number of high-quality
3D homology models that can be built for endogenous and exogenous interactions [52].
In this work, I probe high-resolution principles governing exogenous and endogenous
PPI networks using a domain-resolved approach that annotates proteins with known do-
mains, and PPIs with known domain-centric interaction mechanisms (domain-domain in-
teractions and domain-motif interactions; Figure 2.1). This domain-resolved network is of
higher accuracy than the binary PPI network, and of higher coverage than the 3D struc-
tural interaction network. Although domain-based studies of host-pathogen PPIs have been
previously reported for specific pathogens [90, 163], a systematic, quantitative comparison
between exogenous and endogenous PPI networks at the level of domains has never been
attempted before. Domain-motif interactions have been previously reported to be impor-
tant in host-pathogen interactions [32], but their prevalence in the global host-pathogen
interaction network remains unknown relative to the within-host network [32]. This global,
domain-resolved map of human-virus and within-human PPI networks enables, for the first
time, the discovery of novel systematic and statistically significant differences between ex-
ogenous and endogenous PPIs in terms of domain interaction usage. While two human
proteins competing to bind the same domain tend to have global sequence similarity, vi-
ral proteins competing with human proteins do not. Viral proteins preferentially target
human proteins containing linear motif-binding domains independent of their degree in
the endogenous network. In addition, viral proteins use linear motifs to mediate protein-
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protein interactions more often than human proteins do. Finally, viral proteins contain a
higher density of linear motifs than generic human proteins. Collectively, these observa-
tions suggest that the exogenous network is very different from the endogenous network in
terms of domain interaction usage. While the endogenous network evolves largely by gene
duplication followed by divergence, the exogenous network is dominated by convergent
evolution of domain-motif and domain-domain interactions. Compared to human pro-
teins, viral proteins tend to convergently evolve and pack multiple linear motifs mediating
many biophysical interactions that are functionally diverse in order to manipulate complex
host processes. Together, these results strongly support the utility of a domain-resolved
approach for interrogating host-pathogen interaction networks, and in particular for deter-
mining the general principles that distinguish exogenous and endogenous interactions.
2.3 Methods
2.3.1 Assembling endogenous and exogenous protein-protein interaction data
I collected reports of endogenous (human-human) protein-protein interactions (PPIs) from
the IntAct database, and reports of exogenous (human-virus) PPIs from the IntAct and
VirusMINT databases [11, 23]. I discarded PPIs with missing protein sequence information
in UniProt [29]. Exogenous PPIs were further filtered to exclude (i) virus species that do
not normally target mammalian hosts, and (ii) deltaviruses, which (as subviral satellites)
cannot infect a host without co-infection by another virus. The viral proteins represent 17
viral families and all Baltimore classes [12].
2.3.2 Annotating protein-protein interactions with domains and interaction
mechanisms
I assigned Pfam domains to the human and viral proteins in the networks using the Pfam
batch search utility, subject to an E -value cutoff of 10−2 [147]. To avoid misclassifying
proviral fragments in the human proteome as native human domains, I removed human
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proteins from the analysis if they were annotated as viral fragments or polyproteins in
Uniprot. Using protein sequence and domain information, I then assigned putative inter-
action mechanisms to endogenous and exogenous PPIs in the dataset. I classified PPIs as
domain-domain interactions (DDIs) if a domain in the first protein was known or predicted
to interact with a domain in the second protein. Pairs of putative interacting domains were
assembled from the DOMINE database [149], which integrates results from a variety of DDI
curation and prediction studies. In addition, I classified PPIs as domain-motif interactions
(DMIs) if one of the proteins contained a putative linear motif-binding (LMB) domain
and the second protein contained a linear motif recognized by that LMB domain. I uti-
lized predicted domain-motif associations from Neduva et al. [137] and manually curated
domain-motif associations from the database of Eukaryotic Linear Motifs (ELM) [36]. Mo-
tifs in these datasets take the form of regular expressions which can be searched directly
against an amino acid sequence using standard pattern matching tools.
2.3.3 Comparison of datasets and statistical analyses
To assess the quality of the endogenous and exogenous networks, I compared them indi-
vidually against a gold standard set of endogenous and exogenous PPIs; these subsets of
interactions were constructed by querying for interactions that were reported by at least
two independent publications.
I measured concordance between having an LMB domain and being a viral target by
picking pairs of human proteins with the same degree in which one had an LMB domain
while the other did not. The protein pair was concordant if the LMB domain-containing
protein was a viral target and the LMB domain-free protein was not a viral target. Con-
versely, the protein pair was discordant if the LMB domain-containing protein was not a
viral target and the LMB domain-free protein was a viral target. All other protein pairs
were considered to be non-informative. To evaluate the statistical significance of this test,
I completed 1,000 repetitions of random permutation of the LMB domain and viral target
annotations among sets of human proteins with the same endogenous degree and repeated
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the procedure.
For permutation-based comparisons of virus and human proteins, I first compute the
mean of each group and then evaluate the difference between these means. To evaluate if
such a difference is likely to arise at random, I repeatedly permute the “virus” and “human”
protein labels and then calculate the difference in the means of the newly randomized
groups. Over a large number of trials (e.g. 1000), the fraction of permutations in which
the random difference is at least as large as the observed difference approximates the
probability of observing such a difference at random (p-value), and serves as a measure of
the statistical significance of the observed measurement.
2.4 Results
2.4.1 A high-coverage, high-accuracy domain-resolved human-virus interac-
tion network
I constructed high-resolution human-virus (exogenous) and within-human (endogenous)
protein-protein interaction (PPI) networks by annotating proteins and PPIs with known
domain information. I considered two major categories of domain-centric interaction mech-
anisms: domain-domain interactions (DDIs), in which a globular domain from one protein
binds to a globular domain from a second protein (Figure 2.1A), and domain-motif inter-
actions (DMIs), in which a linear motif-binding (LMB) domain from one protein binds to a
short, linear peptide motif in a second protein (Figure 2.1B). Some PPIs can be annotated
with both DDI and DMI mechanisms.
The endogenous portion of this network contains 39,329 PPIs among 9,870 human pro-
teins, of which 48.7% can be assigned to at least one of the two domain-centric mechanisms
(Figure 2.2). There are 8,277 DDIs mediated by 1,164 unique domain types forming 3,209
unique types of interacting domain pairs. In addition, there are 16,785 DMIs mediated by
554 unique LMB domain types (Figure 2.2).
The exogenous portion of this network contains 1,670 interactions between 267 viral
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Figure 2.1: Domain-centric mechanisms of host-virus protein-protein interaction. (A) A
domain-domain interaction (DDI) example [166]: a cyclin domain-containing protein from Saimiriine her-
pesvirus 2 (red) targets a human CDK6 kinase domain (white). (B) A domain-motif interaction (DMI)
example [109]: human retinoblastoma-associated protein (white) contains a linear motif-binding (LMB)
domain which recognizes the peptide motif LxCxE (red) in the human papillomavirus E7 protein.
Figure 2.2: Coverage of human-virus protein-protein interaction network by domain-centric
interaction mechanisms. Fractions of endogenous and exogenous PPIs that can be assigned to different
domain-centric interaction mechanisms (DDIs and DMIs). Each mechanism is illustrated using the symbols
at the left, with the percentage of interactions described by that mechanism given below. An interaction
may be described by more than one interaction mechanism.
proteins and their 954 human protein targets. The viral proteins represent 17 viral families
and 7 Baltimore classes (Table B.1) [12]. 30.5% of all exogenous interactions can be assigned
at least one domain-centric interaction mechanism, which can be further divided into the
following five cases (Figure 2.2). (i) 30 exogenous DDIs involve a human domain homolog
present in a viral protein, presumably due to horizontal gene transfer (Table B.2). (ii) 110
18
exogenous DDIs involve human domains interacting with virus-specific domains. (iii) 443
exogenous DMIs are mediated by an LMB domain-containing human protein binding to a
viral protein with the corresponding linear motif. (iv) 11 exogenous DMIs are mediated
by a viral protein containing a human-like LMB domain binding to a human protein with
the corresponding linear motif (e.g. the SH2 and SH3 domain-containing Src protein from
Avian sarcoma virus, and the kinase domain-containing BGLF4 protein from Epstein-Barr
virus). (v) Exogenous DMIs mediated by virus-specific LMB domains are only just starting
to be characterized [19], and are not represented in this network.
2.4.2 Domain-resolved interactions are of high quality
Annotating exogenous and endogenous PPI networks with domain-centric interaction mech-
anisms yields networks with increased resolution compared to binary networks, while main-
taining high coverage. I annotated proteins with complete taxonomic and Pfam domain
information [29, 147], and PPIs with interacting domain information [36, 137, 149]. These
annotated PPIs are of higher quality than generic PPIs, as measured by the overlap with
a gold standard set of PPIs reported by at least two independent publications (“confirmed
interactions”). Specifically, endogenous interactions annotated with domain-centric mech-
anisms are 52% more likely to be confirmed than non-annotated endogenous interactions
(Figure 2.3), and exogenous interactions annotated with domain-centric mechanisms are
28% more likely to be confirmed than non-annotated exogenous interactions (Figure 2.3).
Hence, in addition to providing mechanistic insights, annotation of endogenous and exoge-
nous interactions with domain interaction information raises my confidence in the accuracy
of the underlying interactions.
2.4.3 Binding site mimicry evolves differently in virus and host proteins
In previous work based on 3D structural models of exogenous and endogenous interactions,
it was demonstrated that viral proteins frequently bind to human target proteins at sites of
existing endogenous interfaces (“interface mimicry”) [51]. Moreover, compared to overlap
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Figure 2.3: Domain-resolved interactions are of high quality. Endogenous (blue) and exogenous
(red) PPIs that are supported by a known DDI or DMI are enriched for confirmed interactions (i.e.,
interactions reported by at least two publications). Endogenous and exogenous PPIs lacking the support
of domain-centric mechanisms are depleted for confirmed interactions. Error bars reflect the standard error
based on 1,000 rounds of bootstrap resampling.
among endogenous interfaces, exogenous-endogenous interface overlap was much less likely
to involve global structural similarity between the two proteins targeting the same interface
[51]. Here, I reexamined this result in the context of the domain-resolved human-virus PPI
network.
In the absence of 3D structural information, it is not possible to determine if two
proteins bind to the same interface on a third protein. However, in the domain-resolved
human-virus PPI network, it is possible to determine if two proteins bind to the same
domain in the third protein (Figure 2.4A-C), which is a prerequisite for interface mimicry.
A similar approach has been previously used in the yeast 3D structural interaction
network to distinguish between singlish-interface hub proteins, which mediate mutually
exclusive PPIs, and multi-interface hub proteins, which mediate multiple simultaneous
PPIs [102]. Among DDIs in the endogenous network, of the 3,493 cases where two hu-
man proteins bind to the same domain of a third human protein, 72% are mediated by
domains sharing significant sequence similarity (Figure 2.4D). In contrast, among DDIs in
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Figure 2.4: Binding site mimicry evolves differently in virus and host proteins. Two proteins
can participate in DDIs with a common target by binding to: (A) different domains in the target; (B) the
same domain in the target using different interaction domains; or, (C) the same domain in the target using
the same interaction domain. (D) Viral proteins are significantly less likely than human proteins to bind
to the same domain of a human protein by means of domain sequence similarity to an endogenous binding
partner (Fishers exact test, two-tailed P < 10−10).
the combined exogenous-endogenous network, of the 46 cases where a viral protein and a
human protein bind to the same domain of another human protein, only 24% are mediated
by domains sharing significant sequence similarity (Figure 2.4D). The results from these
domain-resolved analyses are consistent with previous findings using 3D structural net-
works: viral proteins are significantly less likely than human proteins to bind to the same
domain of a human target protein by means of global sequence similarity to an endogenous
binding partner (Fisher’s exact test, two-tailed P < 10−10; Figure 2.4D).
2.4.4 Viruses tend to target LMB domain-containing human proteins
Viruses have been known to use linear peptide motifs to target endogenous LMB domains
[32, 53]; however, it is unknown how prevalent this mechanism of interaction is. Here, I
quantified how frequently viral proteins target host proteins using a domain-motif inter-
action mechanism. I examined the domain composition of human proteins targeted by
viruses, and compared it with the domain composition of generic human proteins in the
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network. I found that human proteins targeted by viruses are significantly enriched for
LMB domains relative to generic human proteins (Fold enrichment = 1.36; Fisher’s exact
test, two-tailed P < 10−15; Figure 2.5). With the exception of Orthomyxoviruses, the
direction of this trend holds for exogenous interactions from all major viral families in the
network, and cannot be attributed to a specific type of virus (Figure 2.5). In contrast,
the difference in enrichment for non-LMB domains between human proteins targeted by
viruses and generic human proteins is only marginally significant (Fold enrichment = 0.96;
P = 0.012; Figure 2.5), suggesting that the observed enrichment for LMB domains among
human proteins targeted by viruses is not a simple result of superior domain annotation
among these proteins.
Figure 2.5: Viruses tend to target human proteins containing linear motif-binding (LMB)
domains. I compared domain composition of generic human proteins in the endogenous network (blue) to
human proteins targeted by viruses (“viral targets”, red). The vertical axis indicates the fraction of proteins
in a group containing LMB domains; the horizontal axis indicates the fraction of proteins containing non-
LMB domains. Relative to generic human proteins, human proteins targeted by viruses are significantly
more likely to contain an LMB domain (vertical axis; Fishers exact test, two-tailed P < 10−15), and are
slightly less likely to contain non-LMB domains (horizontal axis; P = 0.012).
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2.4.5 Preferential targeting of LMB domains by viruses is independent of host
protein degree
Previous work has revealed a tendency for viral proteins to target host protein hubs
[40, 90, 163]. Because LMB domains recognize small peptide motifs which may occur
in many proteins, I expect LMB domain-containing human proteins to participate in more
endogenous interactions than proteins without LMB domains, and hence be more hub-like.
Indeed, the average LMB domain-containing human protein in the network participates in
10.5 endogenous interactions, while the average LMB domain-free protein participates in
only 6.4 endogenous interactions. As a result, my finding that viruses tend to target LMB
domain-containing proteins may be confounded by the viral preference for targeting hub
proteins.
I examined the effects of endogenous degree on the relationship between a human pro-
tein containing an LMB domain and the likelihood of that protein being a viral target. I
stratified human proteins according to endogenous degree and then compared the proba-
bility of being a viral target among proteins with and without LMB domains (Figure 2.6).
Consistent with previous findings that viruses target host protein hubs, I observe that the
probability of being a viral target increases with increasing endogenous degree, and that
this trend holds for both LMB domain-containing proteins and LMB domain-free proteins
(Figure 2.6). More importantly, for a fixed endogenous degree, LMB domain-containing
human proteins are more likely to be targeted by viruses than human proteins without
LMB domains (Figure 2.6). This finding suggests that viruses preferentially target LMB
domain-containing human proteins independent of their higher average degree.
To quantify the statistical significance of this assertion, I measured concordance between
(i) having an LMB domain and (ii) being a viral target, among pairs of human proteins
with the same degree. I picked a pair of proteins with the same degree in which one had
an LMB domain while the other did not, and considered the pair concordant if the LMB
domain-containing protein was a viral target whereas the LMB domain-free protein was
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Figure 2.6: Preferential targeting of LMB domains by viruses is independent of host protein
degree. I partitioned human proteins into LMB domain-containing proteins (filled green points), and LMB
domain-free proteins (open black points). I further divided proteins according to endogenous degree. 92%
of all human proteins in the network fall into one of the degree 1-20 bins; each bin contains at least 20
proteins. The probability of being a viral target increases with degree for both LMB domain-containing
and LMB domain-free proteins. For a given degree, LMB domain-containing proteins are more likely to be
viral targets than LMB domain-free proteins.
not, and discordant if the LMB domain-containing protein was not a viral target whereas
the LMB domain-free protein was. I observed a strong preference for concordant protein
pairs over discordant protein pairs (58% concordant versus 42% discordant), favoring a
degree-independent association between LMB domain-containing proteins and viral targets.
The degree-independent association between a human protein containing an LMB domain
and being a viral target is statistically significant (one-tailed P = 0.006; Figure 2.6), as
calculated by a degree-preserving random permutation of LMB domain and viral target
annotations among sets of human proteins.
2.4.6 Viral proteins have a higher fraction of domain-motif interactions than
human proteins
The results of the previous section establish that viruses tend to preferentially target human
proteins containing LMB domains by comparing properties of human proteins targeted by
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viruses against all other human proteins. Next, I determined if the viral preference for
targeting LMB domain-containing proteins also holds at the level of PPIs, when compar-
ing the fraction of domain-motif interactions (DMIs) between viral proteins and human
proteins.
I observed that viral proteins have higher fraction of DMIs out of total number of PPIs
per protein than human proteins (permutation test, two-tailed P = 0.047; Figure 2.7A). To
ensure this trend was not due to superior annotation in either the endogenous or exogenous
dataset, I repeated the analyses on confirmed interactions and observed the same trend
(P = 0.018; Figure 2.7B). This result suggests that although the endogenous network
contains more proteins and PPIs and has a higher fraction of domain annotation than
the exogenous network (Figure 2.2), viral proteins are more likely on average than human
proteins to interact using a domain-motif interface (Figure 2.7).
Figure 2.7: Viral proteins have a higher fraction of domain-motif interactions (DMIs) than
human proteins. Fraction of DMIs out of the total number of interactions per protein tend to be higher
in viral proteins (red) than human proteins (blue) in (A) all interactions in the network (permutation test,
two-tailed P = 0.047), and (B) confirmed interactions (P = 0.018). Error bars reflect the standard error.
2.4.7 Viral proteins target LMB domains at greater density than human pro-
teins
I next examined whether viral preference for targeting LMB domain-containing proteins
is reflected in elevated linear motif occurrence in viral proteins as compared to human
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proteins. I determined density of linear motifs and LMB domains targeted per protein,
rather than directly comparing the total number of linear motifs and LMB domains targeted
per protein, to account for the large difference in protein size between viral and human
proteins: within the network, the median viral protein length (306 residues) is 34% smaller
than the median human protein length (464 residues).
I first calculated the density of unique LMB domains targeted per residue for viral pro-
teins and human proteins. I found that viral proteins target a greater variety of unique LMB
domains per residue than human proteins (permutation test, two-tailed P = 0.012; Fig-
ure 2.8A). This calculation directly compares the properties of experimentally determined
endogenous and exogenous PPIs, and may be confounded by methodological differences in
mapping endogenous versus exogenous interactions: only 22% of endogenous interactions
are reported by small-scale experiments (reporting fewer than 100 interactions), whereas
as many as 73% of exogenous interactions are reported by small-scale experiments. To
ensure that the aforementioned trend observed in the network cannot be explained by this
difference in methodology, I repeated the analyses on a host-virus PPI network built from
the previously published “HI-2005” and “VirHost” interactome datasets, which were gen-
erated using the same methodology [156, 157], and observed the same trend (P = 0.049;
Figure 2.8A). This analysis supports my earlier conclusion that viral proteins interact with
a greater variety of distinct LMB domains on a per residue basis than human proteins.
The observation that viral proteins target more LMB domains per residue than hu-
man proteins may still be confounded by subtle differences in experimental procedures
for mapping endogenous versus exogenous interactomes. To control for such differences,
I calculated the density of linear motif types per residue for each viral and human pro-
tein, regardless of whether the motifs were used to mediate known interactions. This
measure is interactome-independent, and thus is free of any procedural biases in experi-
mental interactome maps. Consistent with my previous findings, I found that viral proteins
have significantly more unique linear motif types per residue than human proteins (P <
0.001; Figure 2.8B). These results indicate that in addition to preferentially targeting
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Figure 2.8: Viral proteins target LMB domains at greater density than human proteins. Viral
proteins (red) target significantly more unique LMB domains per residue than human proteins (blue) in (A)
all interactions in the network (permutation test, two-tailed P = 0.012), and an independently generated
human-virus PPI network [156, 157] (P = 0.049). (B) Viral proteins also have significantly more unique
LMB motif types per residue than human proteins (P < 0.001). Error bars reflect the standard error.
LMB domain-containing proteins (Figures 5 and 6), viral proteins are more likely to target
a greater variety of unique LMB domains per residue than human proteins (Figure 2.7),
and have a higher density of unique linear motifs than human proteins (Figure 2.8).
2.5 Discussion
I constructed a domain-resolved map of host-virus and within-host protein-protein inter-
action (PPI) networks to probe general, systems-level principles that distinguish host-
pathogen, exogenous PPIs from within-host, endogenous PPIs. Annotation of proteins
and interactions with known domain information yields a domain-resolved network with
higher resolution and quality than the binary PPI network, and higher coverage than the
3D structural interaction network. Classification of endogenous and exogenous PPIs into
domain-domain interactions (DDIs) and domain-motif interactions (DMIs) reveals global
differences in domain interaction patterns between host-pathogen and within-host networks
that are otherwise hidden in traditional binary PPI networks. While these domain-centric
annotations reduce the rate of false positives in PPI networks, additional potential limi-
tations include false negatives, incomplete annotation, and methodological biases. In this
work, I have minimized the effects of such incompleteness and biases by carefully controlling
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for them when performing systematic comparisons between exogenous and endogenous net-
works. A potentially more significant limitation is investigator bias: most host-pathogen
studies are conducted on clinically significant human pathogens, such as HIV. Despite
this investigator bias, this exogenous network represents a wide variety of viral families
(Table B.1). I emphasize that these comparisons and contrasts between exogenous and
endogenous PPIs are carried out within the domain-resolved interaction networks, and
therefore my conclusions should be minimally confounded by systematic biases inherent in
a domain-resolved approach.
These analyses reveal systematic, mechanistic differences between exogenous and en-
dogenous interactions. The most pronounced of these differences is the tendency for viruses
to mimic human interactions by means of convergent evolution. I find that viral proteins
and human proteins tend to target the same domain of another human protein without
any shared sequence similarity, extending the results of previous work using 3D struc-
tural interaction networks [51]. In addition, I demonstrate for the first time that viral
proteins are more likely than human proteins to mediate interactions using short linear
motifs, which can easily arise by convergent evolution due to their small size and minimal
genomic constraints. These observations support the hypothesis that viral proteins tend
to convergently evolve mechanisms to mimic existing endogenous binding interfaces. In
addition, viral proteins are more economical and functionally more pleiotropic than hu-
man proteins in that viral proteins target more LMB domain-containing proteins, and also
target more unique LMB domains per residue. Furthermore, I found that viral proteins
contain more unique linear motif types per residue. Given the knowledge that linear mo-
tifs in disordered regions tend to be conserved and are more likely to be the target of
binding by LMB domains [151], I further investigated whether or not viral proteins are
more disordered than human proteins. Indeed, I find that viral proteins are enriched for
disorder-promoting residues [21] relative to human proteins (Student’s t-test, two-tailed P
< 0.0001). Additionally, considering only motifs in “disordered regions” (a region ± 10
residues around a motif, containing >60% disorder-promoting residues [21]), I observe that
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viral proteins continue to have higher density of unique linear motif types per residue than
human proteins do (permutation test, two-tailed P < 0.05).
These results demonstrate that viral proteins and virus-host PPIs are in general very
different from host proteins and within-host PPIs: viral proteins are small, complex, multi-
functional polypeptides which can mediate multiple host-virus interactions, typically using
the highly economical and highly pleiotropic method of domain-motif interactions largely
through convergent evolution. These signatures of pleiotropy, economy, and convergent
evolution in the virus-host PPI network are a direct consequence of the intense selection
pressure on viruses to establish and maintain, with very limited genomic resources at their
disposal, extensive and effective physical interactions with the host necessary for their
survival. These global trends are applicable in general to viral proteins and exogenous in-
teractions, and do not reflect a bias in a specific viral type, nor in a specific methodology for
determining PPIs. These results suggest that annotating viral proteins with domain-centric
interaction mechanisms, especially by scanning viral protein sequences for linear motifs,
can provide a novel approach to identifying host protein interaction partners for study. It
may also be possible to use this domain-centric annotation approach to identify therapeu-
tic treatments based on competition for motif binding sites. Thus, this study highlights
the importance of a high-resolution, domain-resolved approach to host-pathogen network
biology for revealing general mechanistic principles governing host-pathogen interactions.
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Chapter 3
Transcriptional Correlates of Disease Outcome in Anticoagulant-Treated
Non-Human Primates Infected with Ebolavirus
3.1 Abstract
Zaire Ebola virus (EBOV) infection in humans and non-human primates (NHPs) is highly
lethal, and there is limited understanding of the mechanisms associated with pathogenesis
and survival. Here, I describe a transcriptomic analysis of NHPs that survived lethal EBOV
infection, compared to NHPs that did not survive. It has been previously demonstrated
that anticoagulant therapeutics increase the survival rate in EBOV-infected NHPs, and
that the characteristic transcriptional profile of immune response changes in anticoagulant-
treated NHPs. In order to identify transcriptional signatures that correlate with survival
following EBOV infection, I compared the mRNA expression profile in peripheral blood
mononuclear cells from EBOV-infected NHPs that received anticoagulant treatment, to
those that did not receive treatment. I identified a small set of 20 genes that are highly
confident predictors and can accurately distinguish between surviving and non-surviving
animals. In addition, I identified a larger predictive signature of 238 genes that correlated
with disease outcome and treatment; this latter signature was associated with a variety
of host responses, such as the inflammatory response, T cell death, and inhibition of viral
replication. Notably, among survival-associated genes were subsets of genes that are tran-
scriptionally regulated by (1) CCAAT/enhancer-binding protein alpha, (2) tumor protein
53, and (3) megakaryoblastic leukemia 1 and myocardin-like protein 2. These pathways
merit further investigation as potential transcriptional signatures of host immune response
to EBOV infection.
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3.2 Introduction
Zaire Ebola virus (EBOV; Filoviridae [1]) infection of humans and non-human primates
(NHPs) can cause viral hemorrhagic fever, an acute systemic illness characterized by fever,
bleeding diathesis, fulminant shock, and death [44]. Although several studies have identified
candidate therapeutics that may mitigate the effects of EBOV infection [46, 47, 55, 58, 59,
60, 83, 92, 152, 178], there are currently no FDA-approved post-exposure treatments for
human use. Despite extensive research on EBOV pathogenesis [56, 57, 82], lifecycle [50],
and interactions with the host [6, 77, 185], there are no standard biomarkers to predict host
immune response to EBOV infection, nor are there biomarkers of drug efficacy or survival
following treatment. Here, I investigated the hypothesis that there are signatures of gene
expression associated with survival in EBOV-infected, anticoagulant-treated NHPs.
Immune response pathways play a key role in EBOV pathogenesis. Infection is char-
acterized by up-regulation of inflammatory mediators such as cytokines and chemokines,
interleukins, interferon-inducible proteins, and tumor necrosis factor alpha (TNFα) [74, 81,
126, 158, 192, 208]. In addition, EBOV infection is associated with an early loss of lympho-
cytes [150, 161] and the dysregulation of coagulopathy. This dysregulation of coagulation
and subsequent hemorrhage are characteristic of EBOV infection [57, 82], and may be due
to the fact that immune mediators are over-expressed by monocytes and macrophages,
which, along with dendritic cells, are primary targets for infection [17, 18, 56]. High-
throughput microarray studies of the immune response of NHPs to EBOV infection have
identified dramatic and early changes in host transcription of genes related to interferon
response, cytokine signaling, and apoptosis [158]. Similarly, studies of endothelial cells sug-
gest that accumulation of cytokines and other pro-inflammatory factors can contribute to
the observed pathologies of EBOV infection [57]. Previous studies of clinical samples from
humans infected with Sudan Ebola virus during the 2000-2001 outbreak suggest that hem-
orrhagic symptoms and death may be associated with acute phase proteins and coagulation
factors [126].
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It has been demonstrated that anticoagulant therapeutics have a positive effect on the
outcome of EBOV disease [55, 83]. Notably, approximately 33% of EBOV-infected NHPs
treated with anticoagulants like recombinant nematode anticoagulant protein c2 (rNAPc2)
[55], and recombinant human activated protein C (rhAPC) [83] survived a 100% fatal
EBOV infection model (Table 3.1). Animals responding to anticoagulant treatment had
lower plasma viremia levels and attenuation of the pro-inflammatory and pro-coagulant
responses in both studies [55, 83], suggesting that these indicators could be markers of in-
creased survival. However, these late-stage markers could not identify whether there were
early transcriptional changes that were associated with survival. In addition, these results
are limited in scope to individual gene and protein assays, which cannot assess the host
immune response to infection from a global, transcriptional viewpoint [55, 83]. To identify
early-stage transcriptional changes, I analyzed an existing microarray dataset that exam-
ined the host gene expression in anticoagulant-treated NHPs. I used this dataset to iden-
tify critical transcriptional changes that differentiate between surviving and non-surviving
NHPs following EBOV infection. These results provide critically distinct assessments of
the host immune response to EBOV infection by identifying not only global changes in
transcription, but also transcription factor activities associated with survival.
Dataset 1 Dataset 2
Study EBOV infected NHPs, treated
with rNAPc2 [55]
EBOV infected NHPs, treated
with rhAPC (Xigris) [83]
Survival 33% (3/9 NHPs receiving
rNAPc2). Mean time to death:
8.3 days (EBOV only); 11.7 days
(EBOV + rNAPc2).
18% (2/11 NHPs receiving
rhAPC). Mean time to death:
8.3 days (EBOV only); 12.6 days
(EBOV + rhAPC).
Number of
Samples
Used*
Survivor - rNAPc2 N/A Survivor - rhAPC N/A
Survivor + rNAPc2 2 Survivor + rhAPC 2
Non-Survivor - rNAPc2 2 Non-Survivor - rhAPC 2
Non-Survivor + rNAPc2 6 Non-Survivor + rhAPC 9
Table 3.1: Summary of methods and results from previous publications.
This table briefly describes the infectious agent, treatment, methods, and results previously been described
in Geisbert et al. [55] and Hensley et al. [83]. Footnotes: EBOV: Zaire Ebola virus. NHP: non-human
primate. rNAPc2: recombinant nematode anticoagulant protein c2. rhAPC: recombinant human activated
protein C. * Remaining animals did not have samples available for cDNA microarray analysis.
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I analyzed the transcriptional profiles of peripheral blood mononuclear cell samples
taken from EBOV-infected NHPs treated with either rNAPc2 or rhAPC, as described
previously [55, 83, 208]. I investigated the hypothesis that gene expression patterns are
associated with survival of EBOV challenge following anticoagulant treatment. A previous
study assessed the global transcriptional response of NHPs to EBOV infection, but was un-
able to identify survival-associated profiles, due to a lack of anticoagulant treatment [158].
Previously, I assessed the global transcriptional response in the context of anticoagulant
treatment, but did not seek to identify upstream transcriptional regulators associated with
survival [208]. Here, I used a new method of analysis to identify gene sets which are asso-
ciated with, and predictive of, survival following post-infection treatment. This approach
identified two sets of statistically significant genes that distinguish between surviving and
non-surviving NHPs. One, a minimal set of 20 genes, showed good discrimination between
survivors and non-survivors, but provided little insight into signaling pathways that might
be correlated with survival. The second, a larger set of 238 genes, identified a number
of genes that were functionally controlled by common transcription factors that have not
been previously associated with EBOV infection in NHPs.
3.3 Methods
3.3.1 Animal experiments and ethics statement
The datasets for this study were collected from previously published results studying the
affect of anticoagulant therapeutics (rhAPC and rNAPc2) on the immune response of
non-human primates (NHPs) to lethal Zaire Ebola virus (H.sapiens-tc/COD/1995/Kikwit-
9510621; EBOV) infection. Experimental methods and results of the rhAPC and rNAPc2
studies have previously been described in Geisbert et al. [55] and Hensley et al. [83],
respectively (Table 3.1). The cumulative dataset used in this study includes 23 rhesus
macaques: 4 untreated controls, 8 rNAPc2-treated NHPs, and 11 rhAPC-treated NHPs
(Table 3.2). A total of 4 NHPs survived lethal challenge with EBOV virus (2 rNAPc2-
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treated and 2 rhAPC-treated).
Group
EBOV
Only (EO)
EBOV-infected,
Treated Non-Survivors
(ETNS)
EBOV-infected,
Treated Survivors
(ETS)
Day/Sample 1 2 3 4 1 2 3 4 5 1 2 3 4
-8 • • • • • • •
0 • • • • • • • • •
3 • • • • • • • • • • •
6 • • • • • • • • • • • •
rNAPc2 – – – – + – – – – + + – –
rhAPC – – – – – + + + + – – + +
Day of Death: 9 8 8 8 8 9 7 7 8 – – – –
Table 3.2: Summary of samples used in this study.
This table depicts the samples (dots) used in this study. Samples are grouped vertically based on treatment,
then by individual animal. Samples are also grouped horizontally by day pre- and post-infection. Summary
information includes applied treatment (if any), and date of death for each animal. Footnotes: EBOV:
Zaire Ebola virus. rNAPc2: recombinant nematode anticoagulant protein c2. rhAPC: recombinant human
activated protein C.
Animal research for these previously published studies was conducted at the United
States Army Medical Research Institute for Infectious Diseases (USAMRIID), in compli-
ance with the Animal Welfare Act and other federal statutes and regulations relating to
animals and experiments involving animals, and adheres to the principles stated in the
Guide for the Care and Use of Laboratory Animals, National Research Council, 1996. The
facility is fully accredited by the Association for Assessment and Accreditation of Labora-
tory Animal Care, International. These experiments and procedures were approved by the
USAMRIID Institutional Animal Care and Use Committee.
3.3.2 Sample preparation and microarray processing
Experimental methods for RNA processing and DNA microarray preparation have been
previously described in Yen et al. [208]. Microarrays were analyzed in R, using the LIMMA
package in Bioconductor [61, 176, 182] and processed as follows: (i) background correction
was done using the subtract method [153]; (ii) within-array normalization was done using
the loess method [177]; (iii) log ratio and log intensity values were calculated; (iv) array con-
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trol probes were removed from the dataset; and, (v) the data were zero-transformed within
each animal using baseline (pre-infection) sample; in the case of multiple pre-infection sam-
ples, Day 0 was used (Figure A.1). The raw microarray dataset was deposited in NCBI’s
Gene Expression Omnibus (GEO; [42]) database (Accession: GSE24943; [208]).
I organized the microarrays into three groups based on NHP response to anticoagu-
lant drug treatment: (i) EBOV-infected NHPs that did not receive anticoagulant treat-
ment (“EBOV Only”; EO); (ii) anticoagulant-treated NHPs that survived EBOV infec-
tion (“EBOV infected, Treated Survivors”; ETS); and, (iii) anticoagulant-treated NHPs
that did not respond to treatment and did not survive EBOV infection (“EBOV infected,
Treated Non-Survivors”; ETNS), which were characterized by a mean time to death in-
distinguishable from untreated NHPs, i.e. animals died prior to Day 10 post-infection. A
fourth group, characterized by treated, non-surviving NHPs with a mean time to death
greater than the untreated controls, was excluded because any results would have been
uninformative with regard to survival or treatment-specific transcriptional signatures. I
limited the microarrays to Days 3 and 6 post-infection, because these timepoints were
available for all treatment groups. A total of 23 arrays were included in the comparison:
4 arrays for each treatment group on both Day 3 and Day 6, except for the EO group on
Day 3, which only had 3 samples (Table 3.2).
3.3.3 Identification of a minimal survival-associated gene set
To identify the minimal number of genes which distinguished survivors from non-survivors,
I grouped the “EBOV Only” and “EBOV infected, Treated Non-Survivors” groups to-
gether into one cumulative “Non-Survivor” (NS) group. I compared survivors against
non-survivors on Day 3, Day 6, and Days 3 and 6 together (Figure A.1). Gene expression
was averaged within each treatment group for individual probes, and the difference in mean
expression (∆M ) for individual probes was calculated as follows:
∆M = |ETS −NS| (3.1)
35
where ETS is the mean expression in survivors (ETS), and NS is the mean expression
in non-survivors (NS). The probe (and its corresponding gene) is considered biologically
relevant if, in at least one of the three comparisons, it meets the following criteria: (i)
statistical significance (Student’s t-test, unequal variance; P ≤ 0.05); (ii) large magnitude
(∆M ≥ 2); and (iii) the differences in individual values across a treatment group are in
agreement with the difference in means (within-group agreement).
3.3.4 Identification of a general survival-associated transcriptional profile
To determine whether there is a general transcriptional profile associated with survival,
I analyzed Day 3 and 6 arrays in EBOV-infected survivors and compared them against
NHPs that did not survive infection using six comparisons: the ETS group to the ETNS
group, and the ETS group to the EO group, at three time points: Day 3, Day 6, and Days
3 and 6 together (Figure A.1). Gene expression was averaged and the difference in mean
expression (∆M ) for individual probes is calculated as follows:
∆M = |ETS −X| (3.2)
where ETS is the mean expression in survivors (ETS), and X is the mean expression in
either of the two non-survivor groups (ETNS or EO). The probe (and its corresponding
gene) was considered biologically relevant if, in at least one of the six comparisons, it met
the previously described criteria.
3.3.5 Statistical analysis and validation
The correlation between identified genes and survival was evaluated for statistical accu-
racy using a permutation test of hierarchical clustering. Expression values for each gene
were randomly permutated among arrays (1000 trials); for each trial, complete linkage
hierarchical clustering was used to evaluate whether the gene list separated NHPs which
survived infection from NHPs that did not survive infection (Pearson correlation coeffi-
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cient). Clustering was completed using PyCluster [34] and Cluster 3.0 [43]. Heatmaps and
dendrograms were generated using Java TreeView [160], and networks were rendered in
Cytoscape [170]. The classification ability of each gene set was evaluated using leave-one
out cross-validation and receiver operating characteristic (ROC) curves. Classification was
evaluated by comparing the sum of normalized distances of the left-out sample to the mean
of the survivor and non-survivor groups, for each gene in the gene set. The area under the
curve (AUC) was used to evaluate performance of each gene set.
Biologically and statistically relevant genes were probed for functional annotation, path-
ways, and upstream transcriptional regulators using the Ingenuity Pathway Analysis suite
of software (IPA; Ingenuity R©Systems, www.ingenuity.com). I confirmed the expression
profile of a subset of this gene set using two comparisons: (1) an independently derived
microarray dataset which examined changes in gene expression in EBOV-infected NHPs
without anticoagulant treatment; and, (2) reverse transcription-PCR. I examined expres-
sion over the course of infection using the following equation:
∆MMA,V DS = |(MAX)− (V DSX)| (3.3)
Where MAX is the mean expression in this dataset on Day 3 or Day 6, and V DSX is the
mean expression in the “Validation Dataset”, either the second microarray dataset or the
RT-PCR, on Day 3 or Days 5/6. I considered “complete agreement” to be a case where
the direction of expression in this dataset and the validation dataset are the same (e.g.
both up-regulated); “minor disagreement” is a case where the direction of expression is
opposing in the microarray and validation datasets, but is within 1 log2 fold change of
difference, and therefore not significantly different; and, “major disagreement” is a case
where the direction of expression in the microarray and validation datasets are opposing
and significant in magnitude (>1). I evaluated whether the RT-PCR results reflect similar
trends in expression, compared to the microarray data, by calculating the percentage of
“complete agreement” or “minor disagreement” cases.
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I compared the 245 probes from this gene set to the second microarray, for EBOV-
infected NHPs that did not receive anticoagulant treatment. Of the 245 probes in this
gene set, only 182 were available on the second microarray for confirmation (74.3%). When
comparing the two microarray datasets, an average of 132.5 probes (72.8%) were in com-
plete agreement or minor disagreement regarding the changes in expression from baseline
to Day 3 or Days 5/6. Of the remaining probes, the majority were cases in which one
microarray dataset was not differentially expressed but the other was, or vice versa; there
were only 8 cases of significant and opposing disagreement between the two microarray
datasets (4.4%).
I also confirmed a subset of this gene set using RT-PCR. Of the 245 probes of interest, I
tested 56 genes that were associated with the upstream transcriptional regulators I identi-
fied previously; of these 56 genes, 45 passed the quality testing. For EBOV-infected NHPs
that did not receive anticoagulant treatment (“EBOV Only”), an average of 34.5 probes
(76.7%) were either in complete agreement or minor disagreement with respect to expres-
sion on Days 3 and 6. For EBOV-infected, anticoagulant-treated NHPs that did not survive
(“EBOV infected, Treated Non-Survivors”), an average of 34 (75.6%) probes were either
in complete agreement or minor disagreement. Finally, for EBOV-infected, anticoagulant-
treated NHPs that survived infection (“EBOV infected, Treated Survivors”), an average
of 37.8 (83.9%) probes were either in complete agreement or minor disagreement between
the microarray dataset and RT-PCR.
3.4 Results
3.4.1 Identification of a minimal survival-associated gene set in EBOV-infected,
anticoagulant-treated NHPs
Previous studies have reported that NHPs exhibit strong transcriptional changes in re-
sponse to EBOV infection [158, 208]. I was interested in determining if these transcrip-
tional changes were altered by anticoagulant treatment; specifically, I was interested to
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determine if there were any transcriptional correlates associated with survival of EBOV
infection.
To determine the minimal number of genes which were associated with survival, I
analyzed changes in mRNA expression in EBOV-infected NHPs with and without antico-
agulant treatment. Previously published data was used to build a cumulative group of 23
EBOV-infected NHPs ([55, 83]; Table 3.1): 4 EBOV-infected controls that did not receive
anticoagulant treatment, 8 EBOV-infected NHPs that were treated with rNAPC2, and 11
EBOV-infected NHPs that were treated with rhAPC (Table 3.2). I organized the sam-
ples into three groups: (i) EBOV-infected, untreated non-survivors (“EBOV Only”; EO);
(ii) EBOV-infected, anticoagulant-treated survivors (“EBOV-infected, Treated Survivors”;
ETS); and, (iii) EBOV-infected, anticoagulant-treated, non-survivors (“EBOV-infected,
Treated Non-Survivors”; ETNS), which were characterized by a mean time to death indis-
tinguishable from untreated NHPs. In order to identify a set of probes which were asso-
ciated with survival and not just treatment responses, I compared the gene expression of
NHPs that survived EBOV infection (ETS) to those that did not survive (“Non-Survivors”,
NS; a combination of the EO and ETNS groups) on Days 3 and 6 post-infection. Probes
were considered of interest if the difference in expression between groups was statistically
significant (Student’s t-test, unequal variance; P ≤ 0.05), with a large change in transcrip-
tional magnitude (∆M ≥ 2), and had within-group coherence (see Section 3.3).
I identified a total of 20 unique probes which differentiated between the NHPs that
survived EBOV infection (ETS) and those that did not (NS). These probes corresponded
to 16 annotated genes, 3 genetic loci, and 1 microRNA (Figure 3.1). There are two obvious
patterns of differentially expressed genes which exhibit significant and opposing regulation
in the two groups (Figure 3.1A): (i) 6 genes have higher expression values in survivors com-
pared to non-survivors (CLDN3, ILF2, ILF3, NDUFA12, RUVBL2, and SLC38A5); and,
(ii) 10 genes have lower expression values in survivors compared to non-survivors (ACCN1,
CEBPE, CRHR2, FAM63A, HMP19, IL2RA, LTF, PSMA1, RCHY1, and SLC9A7). Fi-
nally, the genetic loci (AC009283, LOC100289371, and LOC440871) and microRNA (miR-
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122) also appear to be down-regulated in survivors compared to non-survivors.
Figure 3.1: Identification of a small gene set is sufficient for classification of survival in
EBOV-infected, anticoagulant-treated NHPs. (A) A heatmap depicting the gene expression values
of 20 genes which were found to distinguish between “EBOV-infected, Treated Survivors” (ETS) and
Non-Survivors (“EBOV Only” and “EBOV-infect, Treated Non-Survivors”; see Section 3.3). The days
post-infection are labeled at the top of each column. Blue indicates down-regulation, and red indicates
up-regulation, of genes compared to pre-infection baseline, white indicates no change in expression (scale
indicated). Gene names are listed to the right. (B) A dendrogram depicting hierarchical clustering of
individual samples, using the set of 20 genes (permutation test, one-tailed P < 0.0001). ETS samples are
indicated in green; samples are labeled “groupX Y”, where X is the sample number and Y is the days post-
infection. (C) A ROC curve depicting how accurately this gene set can classify survivors and non-survivors,
based on leave-one-out cross-validation (AUC = 1.00). This gene set is indicated in black, and a random
ROC curve is indicated in grey.
Due to the minimal size of the gene set, it is difficult to perform functional enrichment
or pathway analysis; however, identification of individual gene traits and annotation is
useful for elucidating how individual genes may be associated with viral infection. For
example, over half of these genes have been previously associated with viral infection or
replication, or have been found to physically interact with viral proteins (e.g. CLDN3 [127];
CRHR2 [99]; ILF2 [110, 171]; ILF3 [68, 199]; LTF [2, 15, 189, 190, 214]; miR-122 [116];
RCHY1 [174]; and, RUVBL2 [97]). Importantly, none of these genes have been linked
to EBOV infection, with the exception of ILF3, of which an isoform called DRBP76 is
known to bind EBOV protein VP35 [169]. Although miR-122 has not been associated with
EBOV infection, it is a known positive regulator of the replication of hepatitis C virus,
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another RNA virus [93, 94]. Additionally, several of the genes associated with survival
encode for transport and membrane proteins (e.g. ACCN1, CLDN3, HMP19, NDUFA12,
SLC9A7, and SLC38A5), suggesting that small-molecule transport proteins may play a role
in survival of EBOV challenge. Several gene products are also associated with immune
response or inflammatory response (e.g. CRHR2, IL2RA, LTF, and PSMA1), which is
consistent with previously published studies investigating the effects of EBOV on gene
expression [81, 158, 208].
Having identified a minimal survival-associated gene set, I was interested in determining
whether it could accurately distinguish between survivors and non-survivors. Hierarchical
clustering is a common way to use the characteristics of a gene set to determine if datasets
are similar or dissimilar. I used hierarchical clustering to demonstrate that I could separate
survivors (green) from non-survivors, using only this small gene set with a high degree of
significance (permutation test, one-tailed P < 0.0001; Figure 3.1B). In addition, I evaluated
the cumulative ability of the gene set to distinguish survivors from non-survivors, based
on individual gene traits, using leave-one-out cross-validation. This approach tests the
robustness of a classifier, by using one sample as a testing set and the remaining samples
as a training set, then classifying the left-out sample based on the training set. This
procedure is repeated for all samples, and the robustness of a classifier is evaluated by a
receiving operator characteristic (ROC) curve [7, 65, 173]. Leave-one-out cross-validation
showed that the classifier correctly classified samples with 100% accuracy, i.e. no survivors
were mistakenly classified as non-survivors, or vice versa (AUC = 1.00; Figure 3.1C). This
minimal survival-associated gene set, although small, is able to distinguish NHPs that
survived EBOV infection from NHPs that did not survive infection, in this dataset.
3.4.2 Identification of a general, survival-associated transcriptional profile
Although a minimal gene set can be useful for identifying individual genes associated
with survival, I was also interested to know whether there was a general transcriptional
profile associated with survival. In particular, I was interested to know if NHPs that
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survived EBOV infection displayed coordinated enrichment of specific signaling pathways
or transcriptional responses. To identify a broad, survival-associated transcriptional profile
that was also associated with anticoagulant treatment, I compared the expression profiles
of anticoagulant-treated NHPs that survived EBOV infection (ETS) to NHPs that did not
receive anticoagulant treatment (EO) and to NHPs that received anticoagulant treatment
but did not survive EBOV infection (ETNS). I compared survivors to the two non-survivor
groups (EO or ETNS) on Day 3, Day 6, and Days 3 and 6 together; probes were chosen
according to the previously described criteria (see Section 3.3).
Using this approach, I identified a total of 245 unique probes, corresponding to 238
annotated genes, which accurately differentiated the three groups (Figure 3.2). Hierarchical
clustering of the 245 probes showed that the probes clustered into four gene expression
patterns: (1) down-regulation in the EO group on both days, compared with up-regulation
in survivors on both days; (2) down-regulation in the ETNS group on Day 6, compared
with up-regulation in survivors on both days; (3) up-regulation in the non-survivor groups
on both days, compared with down-regulation in survivors on both days; and, (4) up-
regulation in the non-survivor groups on Day 6, compared with down-regulation in survivors
on both days (Figure 3.2A). In general, the overall pattern of these separate clusters is one
of significant and opposing regulation of expression when comparing NHPs that survived
EBOV infection to NHPs that did not survive infection, regardless of treatment.
Analysis of the overall gene set using Ingenuity Pathway Analysis (IPA; Ingenuity
R©Systems) identified several statistically significant cellular and molecular functions, in-
cluding cell death and survival, cellular growth and proliferation, infectious disease, cell
cycle, and immune cell trafficking. In addition, I probed the 4 gene clusters to deter-
mine if there were any cluster-specific pathways or networks that were functionally en-
riched. I found that the four main clusters were associated with: (1) molecular transport,
cell-mediated immune response, and cell development; (2) cellular growth and prolifera-
tion, drug metabolism, cell death and survival, cell-to-cell signaling and interaction, and
cell cycle; (3) cell-to-cell signaling and interaction, hematological system development and
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Figure 3.2: Survival following anticoagulant treatment is associated with a broad transcrip-
tional profile. (A) A heatmap depicting the gene expression values of 245 probes (238 genes) which
were found to distinguish between “EBOV-infected, Treated Survivors” (ETS), “EBOV-infect, Treated
Non-Survivors”, and NHPs that did not receive anticoagulant treatment (“EBOV Only”; see Section 3.3).
The days post-infection are labeled at the top of each column. Blue indicates down-regulation, and red
indicates up-regulation, of genes compared to pre-infection baseline; white indicates no change in expres-
sion (scale indicated). Probes are grouped into 4 clusters, denoted by numbers to the left of the heatmap.
Functional annotation of each cluster is listed in bold to the right of the heatmap, along with a list of
representative genes associated with the annotation. (B) A dendrogram depicting hierarchical clustering
of individual samples, using the gene set of 245 probes (permutation test, one-tailed P < 0.0001). ETS
samples are indicated in green; samples are labeled “groupX Y”, where X is the sample number and Y is
the days post-infection. (C) A ROC curve depicting how accurately this gene set can classify survivors and
non-survivors, based on leave-one-out cross-validation (AUC = 1.00). This gene set is indicated in black,
and a random ROC curve is indicated in grey.
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function, and cellular growth and proliferation; and, (4) cellular compromise, and cell mor-
phology (Figure 3.2A). In particular, I observed that many of the genes in Cluster 2 were
associated with cell metabolism, suggesting that this process is down-regulated in non-
survivors when compared to survivors. Cluster 3 is also heavily associated with immune
and inflammatory responses, and several genes are expressed predominantly by immune
cells. These functional annotations are consistent with previous studies assessing host im-
mune response to EBOV infection using microarrays [158, 208]. For example, I observed
up-regulation of genes associated with innate immune response, regulation of cytokine and
chemokine production, regulation of apoptosis, and interferon response, as reported in
previous studies [158, 208]. The observed regulation of these genes is consistent with the
hypothesis that non-survivors experience severe dysregulation of the immune response, as
opposed to survivors, which maintain a normal level of expression [158, 208].
To evaluate the classification of this gene set, I hierarchically clustered individual arrays
([37]; complete linkage method; Figure 3.2B). The resulting dendrogram has two major
branches, in which NHPs that survive EBOV infection (green) cluster separately from
those that did not (black; Figure 3.2B), indicating that the expression profiles of survivors
are distinguishable from the expression profiles of non-survivors. Correspondingly, this
gene set is able to accurately distinguish between survivors and the combined non-survivor
groups (permutation test, one-tailed P < 0.0001); however, I found no significant difference
in the expression profiles when comparing the two non-survivor groups. Additionally, this
gene set is capable of perfectly classifying survivor and non-survivor groups (Figure 3.2C).
I used leave-one-out cross-validation to evaluate whether survivors could be distinguished
from non-survivors. I found that cross-validation was able to correctly classify samples
with 100% accuracy, i.e. no survivors were mistakenly classified as non-survivors, or vice
versa (AUC = 1.00; Figure 3.2C). These two tests confirm that the expression profiles
of survivors are distinguishable from the expression profile of non-survivors; however, the
expression profile of untreated non-survivors (EO) is indistinguishable from that of treated
non-survivors (ETNS). Finally, I compared this list of 238 genes against the previously
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identified list of 20 probes which were highly predictive for distinguishing between survivors
and non-survivors. Of the 20 probes, I found that 17 (85%) also appeared in the set of 238
genes. These results confirm that the 238 genes are predictive for distinguishing between
treatment groups and survival outcomes, and that the predictive power is comparable to
the list of 20 highly predictive genes.
3.4.3 Survival-associated genes are transcriptionally interconnected
To further investigate how these survival-associated genes are functionally associated, I
determined if the genes were transcriptionally related, e.g. by being participants in a
major pathway or signaling network, or by having a common upstream transcriptional
regulator. I used IPA to probe the set of 238 genes in order to identify transcriptional
regulators that were common to a large number of genes in this dataset.
This analysis identified four transcription factors whose downstream targets were statis-
tically over-represented in this network: CCAAT/enhancer-binding protein alpha (CEBPA;
Fisher’s exact test, P < 0.0001), tumor protein 53 (p53; P < 0.001), megakaryoblastic
leukemia 1 (MKL1; P < 0.0001) and myocardin-like protein 2 (MKL2; P < 0.0001). The
probability of finding at least as many up-stream transcriptional regulators in a gene set of
245 probes is extremely unlikely, suggesting that this result is not due to random chance
(re-sampling, P ≈ 0.01). The transcription factors and their targets are shown in Fig-
ure 3.3, which shows genes colored according to the difference in mean expression between
NHPs that survived EBOV infection and those that did not.
This network of transcription factors and their downstream targets is highly intercon-
nected, with several transcription factors sharing targets; in particular, MKL1 and MKL2
appear to co-regulate all their targets (Figure 3.3). As would be expected for transcription
factors that are post-translationally activated, the four transcription factors were not them-
selves significantly differentially regulated in this dataset. For each transcription factor, I
compared the expression of the downstream targets in NHPs which survived infection to
NHPs that did not survive infection, to determine if downstream targets correlated with
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Figure 3.3: Survival-associated genes are transcriptionally interconnected. A network illus-
trating transcriptional connections between 37 genes which distinguish between “EBOV-infected, Treated
Survivors” (ETS), “EBOV-infect, Treated Non-Survivors” (ETNS), and NHPs that did not receive antico-
agulant treatment (“EBOV Only”; see Section 3.3). Nodes are labeled with the gene name, edges indicate
regulation of expression from transcription factor to target gene; arrows indicate up-regulation, bars in-
dicate down-regulation, circles indicate up- and down-regulation, and unmarked, light grey edges indicate
unknown regulation. Nodes are colored according to the difference in mean expression between the ETS
and “Non-Survivor” (NS; ETNS and EO) groups; blue indicates lower expression values in the ETS group
compared to the NS group, red indicates higher expression values in the ETS group compared to the NS
group (scale indicated). Nodes that are colored grey (e.g. p53) are master transcriptional regulators which
were not identified as being differentially expressed by my protocol.
survival.
3.4.4 CCAAT/enhancer binding protein alpha (CEBPA)-regulated genes are
down-regulated in NHPs that survive EBOV infection when compared
to non-survivors
Of the 238 genes associated with a transcriptional pattern correlated with survival, 13 genes
are transcriptionally regulated by CEBPA (Figure 3.4). Of these, 2 probes (CEBPE, and
IFI6) distinguished NHPs that survived infection (“EBOV-infected, Treated Survivors”;
ETS) from those that did not (“Non-Survivors”; NS). Both probes had lower expression
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values in the ETS group. Five probes distinguished between survivors and “EBOV-infected,
Treated Non-Survivors” (ETNS); 3 of these probes had higher expression values in survivors
(ARL4C, CDC37, and PCNA), and 2 had lower expression values in survivors (ISG15 and
S100A9). Six probes distinguished between survivors and the “EBOV Only” (EO) group,
of which 4 had lower expression values in survivors (CFD, FOXO3, HPR, and PTGS1).
One probe, SPINT2, distinguished between survivors and the EO group only on Day 6.
One gene, LTF, was identified by two non-identical probes; one probe distinguished sur-
vivors from both non-survivor groups, whereas the other probe only distinguished between
survivors and the “EBOV Only” group. In both cases, the probe had lower expression
values in survivors (Figure 3.4A).
To confirm this expression pattern, I used RT-PCR to examine a subset of the CEBPA-
regulated genes. I examined 11 of the 13 genes by comparing the changes in expression
on Days 3 and 6 in the microarray dataset to the RT-PCR dataset (see Section 3.3). The
RT-PCR dataset reflected the trends observed in the microarray dataset with above 50%
accuracy in all three treatment groups (EO: 7.5 genes, 68.2%; ETNS: 8.5 genes, 77.3%;
ETS: 9.8 genes, 88.6%). For CEBPA-regulated genes, the RT-PCR confirms the expression
trends observed in the microarray dataset.
The observed expression patterns of the downstream targets are consistent with de-
creased transcriptional activity of CEBPA (Figure 3.4B), when compared to a previous
study which identified transcriptional targets of CEBPA (GEO accession GSE2188, [63]).
Although there is a clear pattern of expression that suggests an underlying biological mech-
anism (i.e. down-regulation of CEBPA), this set of probes alone is insufficient to statis-
tically distinguish between NHPs that survived EBOV infection and those that did not.
Hierarchical clustering of CEBPA target expression patterns in individual arrays reveals a
dendrogram in which the survivor and non-survivor groups are not discrete (Figure 3.4C;
ETS indicated in green). There is some similarity between the expression profiles of sur-
vivors (green) and non-survivors, especially treated non-survivors (ETNS), which appears
to be driven by within-animal responses, and not by treatment or survival (Figure 3.4C).
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Figure 3.4: CCAAT/enhancer binding protein alpha (CEBPA)-regulated genes are down-
regulated in NHPs that survive EBOV infection when compared to non-survivors. (A) A
heatmap depicting the gene expression values of 14 probes (13 genes) which are transcriptionally regulated
by CEBPA. The days post-infection are labeled at the top of each column. Probes are grouped according to
which comparison identified them, listed to the left. Gene names are listed to the right. Blue indicates down-
regulation, and red indicates up-regulation, of genes compared to pre-infection baseline, white indicates no
change in expression (scale indicated). (B) A network illustrating transcriptional connections between the
14 genes and CEBPA. Blue indicates lower expression values in “EBOV-infected, Treated Survivors” (ETS),
compared to “Non-Survivors” (NS), red indicates higher expression values in the ETS group compared to the
NS group (scale indicated). Grey nodes (e.g. CEBPA) were not identified as being differentially expressed
by my protocol. (C) A dendrogram depicting hierarchical clustering of individual samples, using the gene
set of 14 probes. ETS samples are indicated in green; samples are labeled “groupX Y”, where X is the
sample number and Y is the days post-infection. (D) A ROC curve depicting how accurately this gene set
can classify survivors and non-survivors, based on leave-one-out cross-validation (AUC = 0.92). This gene
set is indicated in black, and a random ROC curve is indicated in grey.
48
However, I found that leave-one-out cross-validation was able to correctly classify sam-
ples with high accuracy, i.e. very few survivors were mistakenly classified as non-survivors
(AUC = 0.92; Figure 3.4D). This result demonstrates that, when considering the CEBPA
signature as a classifier, survivors are distinguishable from non-survivors, but with less
accuracy than the full gene sets identified in Figures 3.1 and 3.2.
3.4.5 Tumor protein 53 (p53) regulates transcription of some survival-associated
genes
I identified 26 probes, corresponding to 26 genes, which are transcriptionally regulated by
p53 (Figure 3.5A). Of these, 2 probes (CDC42 and ISG15) distinguished NHPs that sur-
vived EBOV infection (“EBOV-infected, Treated Survivors”; ETS) from those that did not
(“Non-Survivors”; NS); in addition, both probes had lower values in survivors. Nine probes
distinguished between survivors and “EBOV-infected, Treated Non-Survivors” (ETNS), of
which 7 had higher expression in survivors (BMP1, KRT8, MDH2, PCNA, PLTP, POLD2,
and TGFBI), and 2 had lower expression values in survivors (CDK2 and TTK). Fifteen
probes distinguished between survivors and the “EBOV Only” (EO) group, of which 7 had
higher expression values in survivors (ADH5, CSTF1, FAM3C, FXYD3, H2AFX, PRDX2,
and RPSA), and 8 had lower expression values in survivors (BCL2L1, FERMT2, FOXO3,
GSTM5, MVK, PSMA1, PTGS1, and SERPINB9; Figure 3.5B). However, the observed
expression patterns of these targets were not consistent with any clearly defined activation
or repression of p53, suggesting that the transcription factor may be differently regulated
in different cell types within the PBMC population.
To confirm this expression pattern, I used RT-PCR to examine a subset of the P53-
regulated genes. I examined 20 of the 26 genes (76.9%) by comparing the changes in expres-
sion on Days 3 and 6 in the microarray dataset to the RT-PCR dataset (see Section 3.3).
The three treatment groups had comparable levels of agreement between the RT-PCR
dataset and the microarray dataset (EO: 14 genes, 70%; ETNS: 14.5 genes, 72.5%; ETS:
16 genes, 80%). For P53-regulated genes, the RT-PCR confirms the expression trends
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Figure 3.5: Tumor protein 53 (p53) regulates transcription of some survival-associated genes.
(A) A heatmap depicting the gene expression values of 26 probes (26 genes) which are transcriptionally
regulated by p53. The days post-infection are labeled at the top of each column. Probes are grouped
according to which comparison identified them, listed to the left. Gene names are listed to the right. Blue
indicates down-regulation, and red indicates up-regulation, of genes compared to pre-infection baseline,
white indicates no change in expression (scale indicated). (B) A network illustrating transcriptional con-
nections between the 26 genes and p53. Blue indicates lower expression values in “EBOV-infected, Treated
Survivors” (ETS), compared to “Non-Survivors” (NS), red indicates higher expression values in the ETS
group compared to the NS group (scale indicated). Grey nodes (e.g. p53) were not identified as being
differentially expressed by my protocol. (C) A dendrogram depicting hierarchical clustering of individual
samples, using the gene set of 26 probes (permutation test, one-tailed P < 0.0001). ETS samples are
indicated in green; samples are labeled “groupX Y”, where X is the sample number and Y is the days post-
infection. (D) A ROC curve depicting how accurately this gene set can classify survivors and non-survivors,
based on leave-one-out cross-validation (AUC = 0.88). This gene set is indicated in black, and a random
ROC curve is indicated in grey.
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observed in the microarray dataset.
In a comparison to an independently derived dataset examining the effects of p53
dosage, I found that approximately 50% of the p53 targets had an expression pattern
concordant with p53 activation, whereas the other 50% had discordant expression patterns
which suggested inhibition or down-regulation of p53 (GEO accession GSE11547, Hosako
et al.). Because a consensus pattern of expression could not be established, I cannot
draw conclusions about the activity of p53 in NHPs that survived EBOV infection when
compared to non-survivors. Despite this lack of consensus regarding the activity of p53
in different treatment groups, hierarchical clustering revealed that this set of probes is
able to distinguish survivors and non-survivors with some accuracy (Figure 3.5C; ETS
indicated in green; permutation test, one-tailed P < 0.0001). The observed dendrogram
has three major branches: (i) an ETS cluster, which is clearly separated from the other
branches of the tree; (ii) an ETNS cluster with two misclassified arrays, which are EO
and ETS samples; and, (iii) an EO cluster. This suggests that the gene set is sufficient
to distinguish survivors from non-survivors, and secondarily can also distinguish the two
non-survivor groups from one another. The case of a survivor array being misclassified as
a non-survivor array is understandable, given that the array sample is from Day 3, when
gene expression differences are relatively small between all different treatment groups. I
found that leave-one-out cross-validation was able to correctly classify samples with some
accuracy (AUC = 0.88; Figure 3.5D), although the classification is not as strong as the
full dataset. These results suggest that survivors are distinguishable from non-survivors,
and furthermore that the overall expression profile of treated non-survivors (ETNS) is
distinguishable from that of untreated non-survivors (EO).
3.4.6 Megakaryoblastic leukemia 1 (MKL1) and myocardin-like protein 2 (MKL2)
jointly regulate some survival-associated genes
Finally, I identified 8 probes, corresponding to 7 genes, whose transcription is jointly reg-
ulated by MKL1 and MKL2 (Figure 3.6). Of these, 2 probes (CEBPE and LTF) distin-
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guished NHPs that survived EBOV infection (“EBOV-infected, Treated Survivors”; ETS)
from those that did not (“Non-Survivors”; NS). Notably, CEBPE is also co-regulated by
another member in the CCAAT-enhancer binding protein family, CEBPA; therefore, it
is included in both gene sets. In addition, 1 probe (S100A9) distinguished between sur-
vivors and “EBOV-infected, Treated, Non-Survivors” (ETNS), and 5 probes distinguished
between survivors and the “EBOV Only” group (EO; BCL2L1, CD151, CTSG, GSTM5,
and LTF). All genes had lower expression values in the survivors than non-survivors (Fig-
ure 3.6A), with the exception of CD151, which exhibited significant down-regulation in
the EO group. Importantly, MKL1 and MKL2 appear to co-regulate the full set of genes
(Figure 3.6B). Notably, the majority of the genes regulated by MKL1 and MKL2 are also
regulated by CEBPA (CEBPE, LTF and S100A9) or p53 (BCL2L1 and GSTM5), suggest-
ing that the regulatory pattern exhibited by these genes could be confounded by regulatory
activity from additional transcription factors.
I confirmed the expression pattern of the 7 genes regulated by MKL1 and MKL2 by
RT-PCR. I examined all genes co-regulated by these transcription factors by comparing the
changes in expression on Days 3 and 6 in the microarray dataset to the RT-PCR dataset
(see Section 3.3). For both non-survivor groups, an average of 5 genes (71.4%) exhibited
the same expression trends in both the microarray dataset and the RT-PCR dataset. For
survivors, an average of 6 genes (85.7%) exhibited the same expression trends in both the
microarray dataset and the RT-PCR dataset. For MKL1 and MKL2-regulated genes, the
RT-PCR confirms the expression trends observed in the microarray dataset.
A previous study found that a double-knockout of MKL1 and MKL2 increases expres-
sion of CEBPE, CTSG, GSTM5, LTF and S100A9, suggesting that MKL1 and MKL2
may jointly act as repressors for these genes under natural conditions [175]. In contrast,
a double-knockout of MKL1 and MKL2 decreases expression of BCL2L1 and CD151, sug-
gesting that MKL1 and MKL2 activate transcription of these genes [175]. The expression
pattern observed with this gene set suggests that MKL1 and MKL2 may be up-regulated
or activated in NHPs that survive EBOV infection, compared to those that do not. Al-
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Figure 3.6: Megakaryoblastic leukemia 1 (MKL1) and myocardin-like protein 2 (MKL2)
jointly regulate some survival-associated genes. (A) A heatmap depicting the gene expression
values of 8 probes (7 genes) which are jointly transcriptionally regulated by MKL1 and MKL2. The days
post-infection are labeled at the top of each column. Probes are grouped according to which comparison
identified them, listed to the left. Gene names are listed to the right. Blue indicates down-regulation,
and red indicates up-regulation, of genes compared to pre-infection baseline, white indicates no change in
expression (scale indicated). (B) A network illustrating transcriptional connections between the 7 genes and
MKL1/2. Blue indicates lower expression values in “EBOV-infected, Treated Survivors” (ETS), compared
to “Non-Survivors” (NS), red indicates higher expression values in the ETS group compared to the NS
group (scale indicated). Grey nodes (e.g. MKL1) were not identified as being differentially expressed by
my protocol. (C) A dendrogram depicting hierarchical clustering of individual samples, using the gene set
of 7 probes. ETS samples are indicated in green; samples are labeled “groupX Y”, where X is the sample
number and Y is the days post-infection. (D) A ROC curve depicting how accurately this gene set can
classify survivors and non-survivors, based on leave-one-out cross-validation (AUC = 0.97). This gene set
is indicated in black, and a random ROC curve is indicated in grey.
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though this observed expression pattern is consistent with what would be observed if MKL1
and MKL2 were activated, this set of probes is too small to distinguish between survivors
and non-survivors groups (Figure 3.6C; ETS indicated in green). A hierarchically-clustered
dendrogram has two major branches, which are each interspersed with EO, ETNS and ETS
samples; this suggests that the overall expression profile of survivors and non-survivors is
not statistically distinguishable. Although the dendrogram suggests that the overall ex-
pression profile in each array is incapable of distinguishing survivors and non-survivors,
evaluation of individual gene contributions using leave-one-out cross-validation shows that
this gene set is capable of classifying samples with extremely high accuracy (AUC = 0.97;
Figure 3.6D). This result demonstrates that survivors can be accurately classified from
non-survivors using the expression of individual genes.
3.5 Discussion
These results show the potential of high-throughput transcriptional studies for identifying
putative markers of survival following EBOV infection. In particular, I identified a minimal
survival-associated gene set that accurately distinguished survival outcome following post-
infection anticoagulant treatment of non-human primates (NHPs) infected with EBOV. I
identified 20 genes that were characterized by significant, coherent and opposing expres-
sion patterns when comparing survivors and non-survivors. Several of these genes exhibit
differential regulation as early as 3 days post-infection, prior to the appearance of clinical
symptoms of EBOV infection; this early differential regulation is especially important for
the identification of early-stage biomarkers to distinguish disease outcomes.
Importantly, several of these genes are associated with different viral infections [2, 15,
189, 190, 214]. Proteins such as ILF3 and RUVBL2 are known to suppress viral replication
in other viruses [68, 97, 199], and I observed that their expression is higher in survivors
than non-survivors. Notably, an isoform of ILF3 is known to bind EBOV protein VP35,
suppressing the function of the viral polymerase [169]. This suggests a mechanism of action
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in which survivors may up-regulate the transcription of certain genes, e.g. ILF3, in order
to suppress viral replication.
I also observed that microRNA 122 (miR-122) is down-regulated in survivors compared
to non-survivors, suggesting that inhibition of miR-122 activity increases survival following
EBOV infection. To date, there have been no studies investigating whether miR-122 inter-
acts with the EBOV genome, but it is well-documented that miR-122 binds the Hepatitis
C virus genome to support the replication of this virus [93, 94]. Comparison of the putative
binding motifs of miR-122 [94] to the consensus sequence of EBOV (Mayinga, Zaire, 1976)
[193] reveals multiple potential binding sites in the viral genome (data not shown). This
suggests that miR-122 is worth further investigation as a regulator of EBOV infection.
Though a minimal set of 20 genes could separate survivors from non-survivors, I was
interested in also studying the general host response to EBOV infection, and to determine
if there was a survival-associated transcriptional profile. I identified 238 genes that ac-
curately distinguished treatment groups and survival outcomes following EBOV infection.
Functional annotation of these 238 genes confirmed that this gene set was comparable
with previously published studies of EBOV infection [81, 150, 158, 208]. In particular, the
expression pattern that I observed for IL6, in which non-survivors are significantly more
up-regulated in early stages of infection than survivors, is supported by similar changes in
protein concentration reported in previous studies [55, 83, 126]. There is also a pattern of
significant up-regulation of genes associated with immune response in non-survivors, but
not in survivors, consistent with the hypothesis that non-survivors exhibit severe dysregu-
lation of the inflammatory response [81, 150, 158, 208]. Importantly, these results highlight
the utility of using a minimal survival-associated gene set to identify individual genes cor-
related with survival following EBOV infection, which is not possible when assessing global
transcriptional responses in the host, as in previous work [158, 208].
When I compared this data to a study of survival-associated biomarkers in human
samples infected with Sudan Ebola virus (SUDV) [126], I found notable similarities. Similar
to this study, I observed significant up-regulation chemokines and cytokines, such as CCL3,
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CXCL10, IL1RN, IL6 and TNF, throughout infection. This study reported that ferritin was
a good correlate of hemorrhage and death in response to SUDV infection [126]. I observed
down-regulation of ferritin throughout infection, although this pattern was not correlated
with survival on a transcriptional level. However, I found that another iron-binding protein,
lactotransferrin (LTF) is highly correlated with survival outcome in EBOV-infected NHPs.
This similarity suggests that iron modulation may play an important role in regulating
filovirus infection, especially in relation to coagulopathies and hemorrhage, and that these
biomarkers merit further study in a human system.
I identified 3 transcriptional modules which were significantly enriched in the gene set:
(i) CCAAT/enhancer-binding protein alpha (CEBPA); (ii) tumor protein 53 (p53); and
(iii) megakaryoblastic leukemia 1 (MKL1) and myocardin-like protein 2 (MKL2). Previous
studies have shown that p53 plays a crucial role during viral infection, which invariably dis-
rupts normal cell cycle processes, in a variety of DNA and RNA viruses [28, 107, 121, 186].
In particular, p53 is known to be associated with the Type I interferon response and has
been previously reported to enhance viral-induced apoptosis in other infections [133, 186].
In my examination of p53-regulated genes, I found that several are associated with regula-
tion of apoptosis (e.g. BCL2L1 [76], CDC42 [184], CDK2 [87], FOXO3 [213], and PCNA
[202]). This may suggest a role for p53 as a mediator of apoptosis following EBOV infection.
However, due to a lack of a consensus pattern of expression, I am unable to determine the
underlying regulation of p53 in this dataset, and therefore cannot draw conclusions about
the activity of p53 in NHPs that survived EBOV infection when compared to non-survivors.
Interestingly, there is no consensus as to how CCAAT/enhancer binding proteins (such
as CEBPA) function in general during viral infection, but they have been previously im-
plicated in promoting the replication of some viruses. For example, CEBP binding sites
exist in the Human immunodeficiency virus (HIV) genome, and CEBPs are required for the
replication and regulation of HIV [78, 79, 168] and Simian immunodeficiency virus [130].
Similarly, physical binding and interactions have been observed between CEBPs and the
proteins of Hepatitis B virus [25, 118], Epstein-Barr virus [205], and HIV [8]. In contrast,
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CEBPs have been known to down-regulate or inhibit replication of T-cell leukemia virus
[70, 84] and some human papillomaviruses [13]. These results suggest that strong CEBP
responses are correlated with poorer prognosis following EBOV infection. I hypothesize
that CEBP-regulated genes may contribute to the inflammatory response to infection, or
to the dysregulation of coagulation.
This study is the first to suggest a role for MKL1 and MKL2 in viral infection, although
roles for both proteins were recently identified in megakaryocyte differentiation and platelet
formation [175]. Because dysregulation of coagulation is a common characteristic of EBOV
infection, it is possible that MKL1 and MKL2 regulate coagulation in response to EBOV
challenge. Indeed, I observed that the downstream targets of MKL1 and MKL2 exhibit
an expression profile consistent with up-regulation of MKL1 and MKL2 in survivors, com-
pared to non-survivors. This implies that survivors increase the regulation of coagulation
processes, potentially avoiding the typical coagulopathies associated with late-stage EBOV
infection. However, the majority of genes that are regulated by MKL1 and MKL2 are also
regulated by CEBPA or p53, suggesting that the regulation observed is not due to the
transcriptional activity of MKL1 and MKL2 alone. Despite this, these genes display a
strong expression profile that is consistent with up-regulation of MKL1 and MKL2 when
compared to a previous study [175], suggesting that survivors are able to recover in part
due to normal MKL1 and MKL2 function.
It is important to note that I did not find a single unique gene that distinguished
between survival outcomes of EBOV-infected NHPs, suggesting that survival following an-
ticoagulant treatment is driven by a complex set of transcriptional responses. In addition,
gene sets and pathways I have identified are associated with survival following anticoagu-
lant treatment, and are therefore specific to this condition. I also stress that the observed
results are in EBOV-infected NHPs, and my findings and conclusions may not be applicable
to additional viral infections, although infection-specific signatures may exist. Under these
conditions, I identify several complex transcriptional responses that clearly differentiate
between survivors and non-survivors following EBOV infection. In particular, I observed
57
several survival-associated profiles that are driven by specific upstream transcriptional reg-
ulators (e.g. CEBPA, p53, and MKL1/MKL2). Notably, these transcription factors have
not been previously associated with EBOV infection, and would not have been identified
without pathway analysis, due to lack of differential regulation. In particular, the ability
of a small set of 20 genes to distinguish between survival outcomes suggests that they
could potentially serve as biomarkers of disease outcome. These results demonstrate that
classification of treatment groups or disease outcome can be accomplished with a small
gene set, which can be useful for identifying individual transcriptional markers associated
with survival following anticoagulant treatment of EBOV infection.
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Chapter 4
The Role of CCAAT-Enhancer Binding Proteins (CEBPs) in Identifying
Transcriptional Correlates of Filovirus Infection
4.1 Abstract
Filovirus infection of humans and non-human primates (NHPs) can rapidly lead to viral
hemorrhagic fever (VHF), which is characterized by severe symptoms such as disseminated
intravascular coagulation, sepsis, and death. Previous studies of host immune response
to infection have identified several transcriptional markers associated with Ebola virus
(EBOV) infection of NHPs. For example, in an analysis of surviving and non-surviving
anticoagulant-treated NHPs infected with EBOV, CCAAT-enhancer binding protein α
(CEBPA) was identified as an upstream transcriptional regulator of survival-associated
genes. Here, I complete a comparative microarray analysis of several publically available
datasets, to determine if transcriptional signatures of CEBP activity are uniquely associ-
ated with Filovirus infection. I compare the expression of CEBPs and their downstream
targets during Filovirus infection, to other infections such as Lassa virus, Lymphocytic
choriomeningitis virus, Dengue virus, and Influenza A (H3N2) infection. CEBPs become
up-regulated in Filovirus infection, but remain unperturbed in response to other viral in-
fections. Genes regulated by CEBPs, such as HP, LCN2 and PTX3, are also up-regulated
in Filovirus infection, indicating that CEBPs are transcriptionally active. Additionally,
I observe up-regulation in genes associated with iron metabolism, suggesting that CEBP
up-regulation may be a part of a larger transcriptional signature. In addition, I observe
up-regulation of genes produced by low-density granulocytes (LDGs), suggesting that these
neutrophils accumulate in the blood of infected NHPs. These findings suggest that iron
metabolism and CEBP up-regulation are closely related and merit further study in the con-
text of Filovirus infection, and that examination of LDGs in infected patients may serve
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as an important marker of the stage of Filovirus infection.
4.2 Introduction
Filoviruses such as Ebola virus (EBOV) and Marburg virus (MARV) can cause severe acute
viral infection of humans and non-human primates (NHPs), which may rapidly lead to viral
hemorrhagic fever (VHF). To date, there are no FDA-approved post-exposure treatments
for human use, although several candidate therapeutics have been proposed, such as siRNA,
recombinant viral vector vaccines, and anticoagulant drugs [46, 47, 55, 58, 59, 60, 83, 92,
152, 178]. Symptoms of EBOV or MARV infection in humans occur roughly two weeks
post-infection, and early-stage symptoms are characterized by fever, general malaise or
weakness, joint and muscle pain, sore throat and coughing, and headache [44, 82]. Symp-
toms progress to include nausea, vomiting, diarrhea, and impaired function of organs such
as kidney and liver. Infection by EBOV leads to Ebola Virus Disease (EVD), which is char-
acterized by disseminated intravascular coagulation, leading to fulminant shock and death
[44]. Early-stage symptoms are clinically indistinguishable from common viral infections,
such as influenza; indeed, similar symptoms can be caused by multiple unrelated infections,
such as malaria, typhoid fever, cholera, leptospirosis, meningitis, etc. Late-stage symptoms
of EBOV infection are similarly indistinguishable from severe systemic infections, such as
Gram-positive or Gram-negative sepsis. It is therefore critical to identify clear signatures of
host response to EVD, which are capable of distinguishing EBOV infection from infections
by other pathogens.
Several high-throughput microarray studies have characterized the host transcriptional
response to EBOV infection in NHPs [158, 208]. Infection triggers classic inflammatory
markers of viral infection, such as up-regulation of chemokines, cytokines, interleukins,
interferon-inducible proteins, and tumor necrosis factor α [158]. In addition to innate im-
mune activation, EBOV infection is associated with dysregulation of apoptosis, destruction
of lymphocytes [150, 161], and potentially, acute phase proteins and coagulation factors
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[126]. Previously, I completed microarray analysis to evaluate the circulating immune re-
sponse of EBOV-infected, anticoagulant-treated NHPs (Chapter 3). Comparative analysis
of surviving and non-surviving NHPs identified a set of 238 genes which were associated
with, and predictive of, survival following EBOV infection. Several of these genes were
functionally controlled by common transcription factors. In particular, CCAAT-enhancer
binding protein α (CEBPA) was identified as an upstream transcriptional regulator of 13
genes; the observed expression of these genes was consistent with decreased transcriptional
activity of CEBPA in survivors compared to non-survivors (Chapter 3).
Many studies have suggested that CEBPs play a role in promoting the replication of
numerous DNA viruses. For example, previous studies report multiple CEBP binding
sites in the Human immunodeficiency virus (HIV) genome [8, 78, 79, 168], and CEBPB
is required for the replication of HIV and Simian immunodeficiency virus (SIV) [79, 130].
Physical interactions between proteins have been reported for CEBPs and the proteins of
Hepatitis B virus, Epstein-Barr virus, and HIV [25, 79, 118, 205]. Previous reports have
also suggested that CEBPs inhibit replication of T-cell leukemia virus and some human
Papillomaviruses [13, 70, 84]. Although CEBPB is the most well-studied CEBP in the
context of viral infections, there are many studies to suggest important roles for CEBPA.
For example, it has been suggested that CEBPA is important in promoting the lytic cycle
in herpesviruses such as Epstein-Barr virus, Kaposi’s Sarcoma-Associated Herpesvirus, and
Human Cytomegalovirus [96, 200, 205]. In addition, CEBPA has been known to promote
the replication of other DNA viruses such as Hepatitis B virus and human Papillomavirus
[25, 75]. A previous study identified CEBPB as a gene associated with lethality in Ebola
virus-infected mouse models, but attributed this to an acute phase response rather than a
signature of CEBP dysregulation [26]. To date, there have been no indicators that CEBPs
are associated with Filovirus infection in humans or non-human primates.
Previous research has suggested a potential role for iron metabolism in Filovirus infec-
tion. A study of clinical samples from humans infected with Sudan Ebola virus (SUDV)
suggests that elevated serum levels of ferritin, an iron-binding protein, was correlated
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with morbidity and mortality [126]. Similarly, in a previous study I found that down-
regulation of another iron-binding protein, lactoferrin, was associated with increased sur-
vival in anticoagulant-treated, EBOV-infected NHPs (Chapter 3). Iron metabolism has
long been known to be associated with innate immunity and viral infections [38, 54,
62, 91, 124, 139, 148]. Interestingly, there are several associations between CEBPs and
iron metabolism. CEBPs are known to regulate several iron metabolism associated genes,
such as hepcidin, the primary regulator of iron metabolism [31, 111, 134, 138]. CEBPA
strongly positively regulates the promoter of hepcidin and many other liver-specific genes
[31, 35, 111]. In addition, CEBPZ, also known as CEBP-homologous protein (CHOP) acts
to suppress hepcidin by binding and inhibiting CEBPA from activating transcription [134].
Many genes associated with iron metabolism are produced by the liver, and signatures of
iron metabolism originating in the liver are not observable in this dataset.
Several iron-binding proteins are known to be produced by neutrophils and other innate
immune cells [91, 103, 183, 212]. In addition, CEBPs are known to be associated with
neutrophil differentiation [16, 113, 114, 131, 212], and mutations in CEBPE are known to
cause neutrophil-specific granule deficiency (SGD), a congenital disease characterized by
incorrect maturation of neutrophils [66, 67, 115]. A transcriptional signature associated
with mature neutrophils would not be observed in these datasets, due to the fact that
these polymorphonuclear cells are expected to separate from the PBMC fraction when
using a Ficoll-density gradient. However, recent studies have suggested that a special class
of neutrophils, called low-density granulocytes (LDGs), can co-purify with PBMCs when
using this protocol [22, 27, 191]. These findings suggest that the transcriptional profile
associated with CEBP up-regulation could be originating from LDGs.
To determine what roles CEBP regulation, iron metabolism, and low-density granulo-
cyte had during Filovirus infection, I used comparative microarray analysis. In addition,
I was interested in determining whether transcriptional signatures of CEBP activity were
associated only with Filovirus infection, or only with VHF infection, or whether dysreg-
ulation of CEBPs was a common response to any viral infection. I used comparative
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microarray analysis of the host response to several pathogenic situations, using previously
published, publically available microarray datasets. I assessed the immune response of
circulating peripheral blood mononuclear cells (PBMCs) in human hosts or NHPs, to a va-
riety of infectious conditions. I assessed several hemorrhagic fever viruses, such as EBOV,
MARV, Lassa virus, Lymphocytic choriomeningitis virus, and Dengue virus. I also com-
pared these datasets to symptomatic Influenza A (H3N2) infection. This analysis suggests
that several CEBPs become up-regulated in response to Filovirus infection, but remain
unperturbed in response to other viral infections, such as Influenza or Dengue virus. Simi-
larly, up-regulation of CEBPs is followed by an increase in the transcription of downstream
targets of CEBPs, including such proteins as haptoglobin (HP), lipocalin-2 (LCN2), and
pentraxin-related protein 3 (PTX3). I do not observe a complete recapitulation of acute
phase response in Filovirus infection, but do see an up-regulation of genes associated with
iron metabolism and LDGs, independent of whether the genes are regulated by CEBPs.
These results indicate that up-regulation of CEBPs following Filovirus infection is a unique
response which is not observed in other viral infections, and that dysregulation of CEBP
activity could lead to dysregulation in iron metabolism, perhaps as a result of LDG activity.
These findings suggest that the CEBP family of transcription factors and their downstream
targets, especially those related to iron metabolism, merit further study in the context of
Filovirus infection.
4.3 Methods
4.3.1 Small-hairpin RNA screen against CCAAT-enhancer binding protein α
The experimental study assessing the effect of a CEBPA knock-down on Ebola virus in-
fection was completed by Claire Marie Filone (Connor Lab; unpublished data). A small-
hairpin RNA (shRNA) was used to knock-down CEBPA in A549 cells, to determine its
effect on the production of EBOV-eGFP. Experimental methods for cell culture, lentiviral
vector infection, puromycin selection, and sample processing are described in Filone et
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al. [48]. Knock-down cells were infected with EBOV-eGFP at MOI 1; experiments were
completed in triplicate. Fluoresence was recorded 3 days post-infection, and background-
corrected by subtracting the average of empty wells in a 96-well plate, then normalized to
100% by the total RFU for each plate. The EBOV receptor, Niemann-Pick disease type C1
(NPC1), was used as a positive control. A gene which had no effect on EBOV replication,
cysteinyl-tRNA synthetase 2 (CARS2), was used as a negative control. The average RFU
for all hairpins to a gene was calculated. Results are presented as percentages compared
to 100% fluorescence of EBOV-eGFP, i.e. no inhibition of EBOV replication.
4.3.2 Data acquisition and annotation
I collected several datasets for analysis in this study from the Gene Expression Omnibus
(GEO [42]; Table B.3). I downloaded the SOFT formatted family files for available datasets,
extracted the expression data for each sample, and supplemented the existing data anno-
tation in each dataset with Entrez Gene and RefSeq mRNA annotations. Datasets were
chosen to limit the number of confounding variables, and several restrictions were applied:
(1) host organism was restricted to Homo sapiens or Macaca fascicularis; (2) sample origin
was restricted to peripheral blood mononuclear cells (PBMCs); and, (3) all chosen datasets
were required to have a control sample for zero-transformation. For these datasets, mi-
croarray processing was limited to zero-transformation of the data against control samples,
followed by calculating averages and standard errors within time points or symptom groups.
4.3.3 Animal experiments and ethics statement
Host immune response to Zaire Ebola virus (EBOV) infection was evaluated on non-human
primates using a sequential sampling study. This study included samples from thirteen
adult male and female cynomolgus macaques (Macaca fascicularis), which were exposed
to lethal doses of aerosolized EBOV. A pre-challenge blood sample was taken from animals
on Day 0, after acclimation, to serve as a baseline for further analysis. Animals were
then anesthetized and exposed individually to a target dose of 1000 PFU of EBOV Zaire
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(Mayinga), in a head-only chamber using an aerosolized method, created by a 3-jet Collision
nebulizer (BGI, Inc., Waltham, MA) and controlled by the automated bio-aerosol exposure
system. The viral preparation used for infection was free of contamination by endotoxin or
mycoplasma. After challenge, blood samples were collected based on approved collection
allowances at various days post-infection when the animals were euthanized.
Animals were obtained from licensed and approved vendors, and research was conducted
at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)
in a BSL-4 laboratory. Research was completed in compliance with the Animal Welfare Act
and other federal statutes and regulations relating to animals and experiments involving
animals, and adheres to the principles stated in the Guide for the Care and Use of Lab-
oratory Animals, National Research Council, 1996. The facility is fully accredited by the
Association for Assessment and Accreditation of Laboratory Animal Care, International.
These experiments and procedures were approved by the USAMRIID Institutional Animal
Care and Use Committee.
4.3.4 Sample preparation and microarray processing
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples. Total
RNA was extracted from samples using TRI Reagant LS (Sigma-Aldrich), and amplified
using the Low-Input Quick Amp Labeling kit (Agilent) before being hybridized to Whole
Human Genome Microarrays (Agilent) along with a pool of reference mRNA. Microarray
images were scanned using the Agilent High-Resolution Microarray Scanner, and features
extracted using the Agilent Feature Extraction software. Microarrays were analyzed in
R, using the LIMMA package in Bioconductor [61, 176, 182] and processed as follows:
(i) background correction was done using the subtract method [153]; (ii) within-array
normalization was done using the loess method [177]; (iii) log ratio and log intensity values
were calculated; (iv) array control probes were removed from the dataset; and, (v) the data
were zero-transformed within each animal using the baseline (pre-infection) sample taken
on Day 0.
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4.3.5 Comparison of datasets and statistical analyses
To determine whether any unique transcriptional signatures were associated exclusively
with viral hemorrhagic fever infections, I compared gene expression in datasets assessing
host response to EBOV, Marburg virus (MARV; Connor et al., under review), Lassa virus
(LASV) [119], Lymphocytic choriomeningitis virus (LCMV) [37], Dengue virus (DENV)
[146], and Influenza virus A/H3N2 (H3N2) [88]. For each dataset, I grouped samples by
time-point (e.g., Day 3) or category (e.g., asymptomatic vs. symptomatic), then calculated
the average expression values and standard errors for each gene within the group. I used
official Gene Symbols to collapse multiple probe identifies into one expression measure-
ment for each gene. For time-course datasets, I additionally grouped samples into early,
middle and late stages of infection (Table B.3). To compare datasets, I identified relevant
Gene Symbols from the literature that were related to CCAAT-enhancer binding proteins
(CEBPs), CEBP-responsive genes, house-keeping genes (HKGs), and interferon-stimulated
genes (ISGs). I extracted these Gene Symbols from each dataset and compared gene ex-
pression values to observe patterns in differential expression that were related to specific
viral infections.
4.3.6 Identification of CEBP-responsive genes
To identify putative targets of CEBPs, I obtained data from a study which developed
zinc-inducible expression vectors against CEBPs A, B, D and E, to examine differential
regulation in NIH 3T3 cells following the induction of these CEBPs [63]. A total of 153
genes reported were by this study to be statistically significantly up- or down-regulated
following CEBP activation. To determine the top-regulated genes, I identified genes whose
expression following CEBP induction was up- or down-regulated by at least 2 log2 fold,
compared to baseline levels. Of the original 153 genes reported, 85 were considered “top
indicators of CEBP activation” (55.5%), of which 50 were available for examination on
both the EBOV and MARV datasets (58.8%). Of these 50 genes, 18 exhibited significant
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levels of differential expression (log2 fold change > 2.0) in NHPs in response to either
EBOV infection or MARV infection (36.0%). Of the 18 genes, 13 genes (72.2%) exhibited
concordant regulation when comparing Filovirus infection to the expression vectors, i.e.
if genes were up-regulated in response to CEBP induction, they were also up-regulated
in either EBOV or MARV infection. I refer to these 13 genes as CEBP-responsive genes
for the remainder of the study. To quantify the differences between EBOV and MARV
infection, I calculated the average relative percentage of up-regulation of a subset of the
CEBP-responsive genes. In particular, I used ABCD2, C3, DCB, HGF, LPL, S100A8, and
SERPINB2, which were up-regulated in both EBOV and MARV infection, but were not as
highly up-regulated as HP, LCN2 or PTX3. I first calculated the relative percentage of up-
regulation for each gene over time, normalized against the highest value of up-regulation.
I then calculated an average and standard error for this set of genes, for both EBOV and
MARV, at each time point.
4.4 Results
4.4.1 A small-hairpin RNA knock-down of CCAAT-enhancer binding protein
α inhibits Ebola virus replication
In a previous study, I examined survival of anticoagulant-treated non-human primates
(NHPs) following lethal Zaire Ebola virus (EBOV) challenge, and found unique transcrip-
tional profiles associated with survival (Chapter 3). In particular, I observed that the tran-
scription factor CCAAT-enhancer binding protein (CEBP) α is associated with survival.
Although I did not observe significant differential regulation of CEBPA itself, I observed
that CEBPA-regulated genes were down-regulated in NHPs that survived EBOV infec-
tion, compared to non-survivors. The observed pattern of expression of CEBP-regulated
genes was consistent with decreased transcriptional activity of CEBPA. I was interested in
determining whether CEBPA had a direct impact on EBOV replication.
To test the effect of CEBPA on EBOV replication, Claire Marie Filone (Connor Lab;
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unpublished data) used a knock-down of several small-hairpin RNAs (shRNAs) against
CEBPA (Figure 4.1). A549 cells were infected with EBOV-eGFP and measured relative
fluorescence 72 hrs later, to determine the amount of viral replication. The effect of a
CEBPA knock-down was compared to two other genes: (1) Niemann-Pick disease type
C1 (NPC1), an EBOV receptor that is essential for EBOV replication; and, (2) cysteinyl-
tRNA synthetase 2 (CARS2), a gene which has no effect on EBOV replication. The
average RFU for all shRNAs targeting a specific gene was calculated, and normalized
against background (0% RFU) and control shRNAs which do not effect EBOV infection
(100%). Knocking down CEBPA inhibits replication of EBOV in A549 cells (Figure 4.1).
Knocking down CEBPA inhibited EBOV replication as well as knocking down NPC1; in
contrast, knocking down CARS2 had no effect on EBOV replication.
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Figure 4.1: A small-hairpin RNA knock-down of CCAAT-enhancer binding protein α inhibits
Ebola virus replication. An shRNA knock-down of CEBPA inhibits replication of EBOV in A549 cells, as
demonstrated by measurement of relative fluorescence (RFUs) of EBOV-eGFP. Measurements were taken 24
hours post-infection of A549 cells with eGFP-expression EBOV. X-axis indicates the gene being targeted by
shRNA. Y-axis indicates the RFUs, normalized to untreated cells infected with EBOV-eGFP. Higher RFU
indicates more replication and production of EBOV-eGFP. CEBPA: CCAAT-enhancer-binding protein;
NPC1: Niemann-Pick disease, type C1; CARS2: cysteinyl-tRNA synthetase 2, mitochondrial (putative);
RFU: relative fluorescence units.
This shRNA screen demonstrated that EBOV replication was inhibited when CEBPA
was knocked down, suggesting that CEBPA is essential for EBOV replication. Coupled
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with previous results which suggested that CEBPA was associated with survival following
EBOV challenge (Chapter 3), this suggested that the CEBP family of transcription factors
merit further investigation as regulators of EBOV infection.
4.4.2 Activating CCAAT-enhancer binding proteins are up-regulated in Filovirus
infection
Based on previous results, and using the shRNA screen, I was interested to determined
whether CEBPA or other CEBPs were uniquely differentially regulated following Filovirus
infection. I examined the gene expression levels of the six CEBPs in non-human primates
(NHPs) infected with Ebola virus (Zaire; EBOV) and in NHPs infected with Marburg virus
(Angola; MARV; Figure 4.2).
I observed a pattern of increased regulation over the course of EBOV or MARV infection
for activating CEBPs, such as CEBPs A, B, D and E (Figure 4.2A). These genes showed
little change in regulation during early stages of infection (Days 1–3), and moderate levels
of up-regulation by middle stages of infection (Days 4 and 5), which continued to increase
in both EBOV and MARV infections until late stages of infection (Days 6–9). I did not
observe consistent up-regulation in all arrays until Day 5 of EBOV infection or MARV
infection. I observed consistent up-regulation by Day 7 of EBOV infection in 2 out of
2 arrays, for CEBPs A, B, D and E. Similarly, on Day 7 of MARV infection I observed
consistent up-regulation in 3 out of 3 arrays for CEBPs B and E. I observed only moderate
up-regulation of CEBPA during EBOV and MARV infection; this pattern was also observed
in a previous study which observed moderate, but not significant, up-regulation of CEBPA
in PBMCs following EBOV infection (Chapter 3). In contrast, CEBPB and CEBPE were
up-regulated in both EBOV and MARV infection by late-stages of infection (e.g., on Day 7).
The up-regulation of CEBPE is consistent with a previous study which identified CEBPE
as becoming differentially expressed in NHPs which survived EBOV infection (Chapter 3).
Interestingly, CEBPD was differentially expressed only in response to EBOV infection, and
no change in differential expression was observed during the course of MARV infection. The
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Figure 4.2: Activating CCAAT-enhancer binding proteins are up-regulated in Filovirus in-
fection. (A) A heatmap depicting the average gene expression for the six CEBP proteins, during EBOV
infection (left) and MARV infection (right). Individual days post-infection are labeled at the top of each col-
umn; gene names are indicated on the left. Blue indicates down-regulation, and red indicates up-regulation,
of genes compared to pre-infection baseline, white indicates no change in expression (scale indicated). (B)
Average CEBP expression over time during EBOV infection (left) and MARV infection (right). Points de-
pict the expression, averaged across probes and samples (y-axis), for each day post-infection (x-axis); error
bars reflect the standard error. Legend is indicated in the upper left. Scale is linear fold-change calculated
from pre-infection levels. (C) Barchart depicting the average CEBP expression on Day 7 post-infection for
EBOV infection (left) and MARV infection (right). Bars indicate the expression, averaged across probes
and samples (y-axis) for each CEBP gene (x-axis); error bars reflect the standard error. Scale is linear
fold-change calculated from pre-infection levels.
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expression of CEBPG and CEBPZ did not change relative to pre-infection levels in either
EBOV infection or in MARV infection.
To clearly depict the timing and significance of expression changes, I averaged the
expression values of each CEBP at each time point, and compared these values to the
overall expression of all CEBPs during pre-infection stages (Figure 4.2B). I observed sev-
eral similarities when comparing EBOV and MARV infections; for example, CEBPs were
up-regulated as early as Day 5 post-infection in both infections. In general, CEBPA was
marginally up-regulated in EBOV infection, reaching a peak up-regulation of 3.6-fold com-
pared to the average pre-infection levels for all CEBPs (1.7-fold increase); however, this
up-regulation was not maintained during later stages of infection. CEBPA was similarly
not up-regulated in MARV infection, increasing by only 1.9-fold by Day 7 post-infection,
compared to the average pre-infection levels for all CEBPs (1.7-fold increase). Compared
to pre-infection levels, CEBPB was significantly up-regulated following both EBOV in-
fection (6.8-fold increase) and MARV infection (4.8-fold increase). Similarly, CEBPE was
up-regulated following both EBOV infection (10.6-fold increase) and MARV infection (11.7-
fold increase; Figure 4.2B).
Although there is a general pattern of agreement when comparing EBOV and MARV
infection, there are also several notable differences. For example, CEBPD was up-regulated
following EBOV infection (6.3-fold increase), but was not differentially expressed following
MARV infection. Additionally, expression of up-regulated CEBPs continued throughout
MARV infection, whereas in EBOV, up-regulation peaked on Day 7 post-infection. I com-
pare the most obvious up-regulation of CEBPs in Figure 4.2C, which illustrates expression
of CEBPs on Day 7 in both EBOV and MARV infection. EBOV is characterized by
temporary up-regulation of CEBPs A, B, D and E, whereas MARV was characterized by
sustained up-regulation of only CEBPs B and E (Figure 4.2C). CEBPs G and Z showed
no statistically significant up- or down-regulation in either infection.
71
4.4.3 CEBP-responsive genes become up-regulated in Filovirus infection
Up-regulation of transcripts for CEBPs led me to investigate whether genes transcription-
ally regulated by CEBPs were also up-regulated. Many inflammatory genes have been
identified as targets of CEBPs, such as IL6, IL1B, and TNF [3, 145, 207]; however, the
expression of these genes is controlled by several different transcription factors, making
it difficult to determine changes in these genes are due exclusively to CEBP activity. To
identify more selective targets of CEBPs, I used data from a zinc-inducible CEBP expres-
sion vector study that identified genes whose induction is strongly dependent on CEBPs
[63]. I characterized CEBP-responsive genes as being genes which were significantly up-
or down-regulated following induction of CEBPs by expression vectors. I identified these
CEBP-responsive genes in the EBOV and MARV infection datasets; in particular, I focused
on genes which were significantly differentially expressed (e.g. log2 fold-change > 2.0) in a
way that was concordant with the expression vector study (e.g. genes up-regulated by the
expression vectors were also up-regulated in EBOV or MARV infection; see Section 4.3).
I identified a total of 13 CEBP-responsive genes which were differentially expressed
following EBOV or MARV infection. To determine whether these genes were transcrip-
tionally regulated by CEBPs, I used pathway analysis software to identify connections
between genes (IPA; Ingenuity R©Systems; Figure 4.3A). The majority of regulation was
moderated by CEBPA (9 genes), CEBPB (7 genes), CEBPD (4 genes) and CEBPE (2
genes). Two CEBPs (CEBPG and CEBPZ) and three CEBP-responsive genes (ABCD2,
GADD45B, and GADD45G) did not have any known transcriptional connections at the
time of this study, based on IPA annotation. Of these 13 CEBP-responsive genes, 10
genes (76.9%) were up-regulated in EBOV or MARV infection (ABCD2, C3, DCN, HGF,
HP, LCN2, LPL, PTX3, S100A8, and SERPINB2; Figure 4.3). When I examined the
expression of these genes in the CEBP induction dataset [63], I found that the expression
was up-regulated for these genes following CEBP induction. The transcriptional pattern
of up-regulation in EBOV and MARV infection is consistent with the hypothesis that
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CEBPs are activating the transcription of these genes. An additional 3 genes (23.1%) were
down-regulated in EBOV or MARV infection, and were also down-regulated in the CEBP
induction dataset (FOS, GADD45B, and GADD45G).
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Figure 4.3: CEBP-responsive genes become up-regulated in Filovirus infection. (A) A network
illustrating transcriptional connections between 6 CEBPs and 13 CEBP-responsive genes. Nodes are labeled
by gene name; arrowed edges indicate regulation of expression from transcription factor to target gene, but
do not indicate up- or down- regulation. CEBPs are depicted as grey nodes, CEBP-responsive genes are
depicted as white nodes. (B) A heatmap depicting the average expression of the 13 CEBP-responsive
proteins, separated into up-regulated and down-regulated groups, during EBOV infection (left), MARV
infection (middle), and in response to activation of a zinc-inducible CEBP-vector (right). Individual days
post-infection for EBOV and MARV are labeled at the top of each column; labels of which vector was
induced are labeled at the top of the CEBP vector column (right). Gene names are indicated on the
right. Blue indicates down-regulation, and red indicates up-regulation, of genes compared to pre-infection
baseline, white indicates no change in expression (scale indicated). Grey indicates a lack of information
about expression for that particular gene.
Having confirmed that most downstream targets of CEBPs are regulated in a way con-
sistent with CEBP activation (10 out of 13 genes, 76.9%), I was interested in more closely
examining the expression of “gold standard” transcriptional targets of CEBPs in response
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to EBOV and MARV infection. I picked three genes which have been reported in the liter-
ature to be transcriptionally regulated by CEBPs: haptoglobin (HP) [35, 108], lipocalin-2
(LCN2) [206], and pentraxin-related protein 3 (PTX3) [104]. These genes were up-regulated
following EBOV and MARV infection as early as Day 5 post-infection (Figure 4.4A). This
up-regulation occurred fairly rapidly after CEBPs themselves are up-regulated, also on
Day 5 (Figure 4.2B), and was sustained throughout both EBOV and MARV infections
(Figure 4.4A), although the magnitude of expression was not as significant in MARV as in
EBOV infection. In addition, LCN2 reached peak levels of up-regulation on Day 8 following
EBOV infection (197.9-fold) and Day 9 following MARV infection (121.5-fold). Similarly,
HP was the most up-regulated on Day 8 following EBOV infection (95.5 -fold) and Day 7
following MARV infection (14.5-fold). PTX3 reached peak levels of up-regulation on Day
8 following EBOV infection (109.5-fold), and Day 9 following MARV infection (89.4-fold)
(Figure 4.4A).
I was also interested to determine whether the expression of CEBP-responsive genes was
correlated with the pattern of expression I observed for CEBPs themselves. I examined the
expression of up-regulated CEBP-responsive genes, not including “gold standard” genes:
ABCD2, C3, DCB, HGF, LPL, S100A8, and SERPINB2 (Figure 4.4B). To quantify the
differences between EBOV and MARV infection, I calculated the average of the relative
percentage of up-regulation over time (see Section 4.3). The average expression of these
genes roughly correlates with the expression of CEBPs over time, for both EBOV and
MARV. Following EBOV infection, expression of these genes increases above 25% by Day
5 post-infection, then peaks at Day 7 post-infection before decreasing; a similar pattern
of expression, with a peak on Day 7, is observed in CEBPs following EBOV infection
(Figure 4.4B). Similarly, MARV infection increases the expression of these genes above 25%
by Day 5 post-infection. There is a slight downward trend of expression on Days 7 and
9, however these time points are statistically indistinguishable from Day 5 post-infection
(Figure 4.4B). Overall this pattern suggests that the expression of CEBP-responsive genes
follows the expression pattern of CEBPs in EBOV or MARV infection.
74
B
A Average Expression of ‘Gold Standard’ CEBP-Responsive Genes
 ∆
 F
o
ld
 C
h
an
g
e;
 L
in
ea
r 
S
ca
le
 9  8  7  6  5  4  3  2  1 
0
50
100
150
200
 HP
 LCN2
 PTX3
 Days Post-Infection 
 ∆
 F
o
ld
 C
h
an
g
e;
 L
in
ea
r 
S
ca
le
 9  8  7  6  5  4  3  2  1 
0
50
100
150
200
 HP
 LCN2
 PTX3
 Days Post-Infection 
Ebola virus (EBOV) Marburg virus (MARV)
Average Expression of Non-’Gold Standard’ Up-regulated CEBP-Responsive Genes
 9  8  7  6  5  4  3  2  1 
 -25
0 
25
50
75
100
 ∆
 F
o
ld
 C
h
an
g
e;
 L
in
ea
r 
S
ca
le
 Days Post-Infection 
Ebola virus (EBOV)
 9  8  7  6  5  4  3  2  1 
 -25
0 
25
50
75
100
 ∆
 F
o
ld
 C
h
an
g
e;
 L
in
ea
r 
S
ca
le
 Days Post-Infection 
Marburg virus (MARV)
Figure 4.4: Average expression of CEBP-responsive genes in EBOV and MARV infection. (A)
Average expression over time of the “gold standard” CEBP-responsive genes (HP, LCN2 and PTX3) during
EBOV infection (left) and MARV infection (right). Points depict the expression, averaged across probes
and samples (y-axis), for each day post-infection (x-axis); error bars reflect the standard error. Legend is
indicated in the upper left. Scale is linear fold-change calculated from pre-infection levels. (B) Average
expression over time of the up-regulated, non-“gold standard” CEBP-responsive genes (ABCD2, C3, DCN,
HGF, LPL, S100A8, and SERPINB2) during EBOV infection (left) and MARV infection (right). Points
depict the expression, averaged across probes and samples (y-axis), for each day post-infection (x-axis);
error bars reflect the standard error. Scale is linear fold-change calculated from pre-infection levels.
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4.4.4 Increase of CEBP mRNA and CEBP targets in PBMCs is a unique
response to Filovirus infection
Having observed that CEBPs become up-regulated following Filovirus infection, I was in-
terested to determine whether this up-regulation was a general response to viral infection,
or whether this signature was unique to Filovirus infection. To test this hypothesis, I exam-
ined the regulation of CEBPs in response to several different viral infections (Table B.3).
To determine if up-regulation of CEBPs was a response to viral hemorrhagic fever, I used
datasets assessing the immune response of NHPs infected with Lassa virus (LASV) [119]
or a Lymphocytic Choriomeningitis Virus (LCMV) that causes a hemorrhagic disease in
NHPs [37]. I also examined a clinical dataset of human immune response to hemorrhagic
cases of Dengue virus (DENV; Flaviviridae) [146]. Finally, to determine whether changes
in CEBPs were due to a general immune response that was not linked to hemorrhagic
complications, I examined a dataset assessing human response to Influenza virus A/H3N2
(H3N2; Orthomyxoviridae) [88], which is a common respiratory infection that does not
cause symptoms of hemorrhagic fever. I examined symptomatic stages of infection for all
viruses.
To evaluate these microarrays objectively, and to determine if the datasets are com-
parable despite their differences in methodology, I examined the expression of standard
house-keeping genes (HKGs) [180], such as actin (ACTB) and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). When I compared pre-symptomatic to post-symptomatic data,
I did not observe significant changes in these HKGs (i.e., genes were less than 2 log2-fold
up- or down-regulated; Figure 4.5A). This pattern of expression was true across all datasets
and all time-points. To further confirm the comparability of these datasets, I examined
the expression of interferon-regulated genes (ISGs). In contrast to HKGs, I expected to
observe significant up-regulation of these innate immune response, in response to any viral
infection [165]. Interferon-induced 17 kDa protein (ISG15) becomes up-regulated in all
datasets compared to pre-infection levels (i.e. >2 log2-fold up-regulated; Figure 4.5A).
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Similarly, oligoadenylate synthetase 1 (OAS1) is highly up-regulated in all datasets except
for DENV infection, in which the up-regulation is only moderate (Figure 4.5A). This anal-
ysis of HKGs and ISGs suggests that differences in CEBP expression between datasets were
due to significant changes in expression, and not due to differences in microarray platforms
or methodology.
Having determined that the dataset had similar expression for HKGs and ISGs, I ex-
amined the post-infection expression of two CEBPs, CEBPB and CEBPE, in all datasets
(Figure 4.5A). In contrast to the significant up-regulation of these genes in Filovirus infec-
tion, I observed no significant levels of up-regulation following infection by Lassa, LCMV,
Dengue or Influenza virus. I observed moderate, but not significant, levels of up-regulation
of CEBPB in LASV and LCMV infection, and moderate up-regulation of CEBPE for
LASV infection, suggesting that up-regulation of these CEBPs may be loosely associated
with hemorrhagic symptoms in NHPs. There was no significant differential expression of
CEBPB or CEBPE in the DENV or H3N2 datasets (Figure 4.5A). I observed no signif-
icant up- or down-regulation of CEBPA, CEBPG, or CEBPZ in any dataset. Similarly,
CEBPD was not up-regulated in any dataset except for EBOV. This pattern of expression
is consistent with the conclusion that up-regulation of CEBPs is uniquely associated with
Filovirus infection.
Similarly, I examined the expression of three “gold standard” CEBP-responsive genes:
HP, LCN2, and PTX3 (Figure 4.5B). Overall, I observed no significant differential expres-
sion of these genes in response to infection by LCMV or H3N2. In general, Filovirus in-
fection caused the highest levels of up-regulation, followed by LASV infection and DENV
infection. In particular, compared to pre-infection levels, late stages of LASV infection
caused up-regulation of HP (3.4 log2-fold) and LCN2 (3.8 log2-fold). Similarly, DENV
infection caused moderate, but not significant, up-regulation of HP (1.4 log2-fold), and
marginally significant up-regulation of LCN2 (2.2 log2-fold). There was no significant up-
regulation of PTX3 following LASV or DENV infection (Figure 4.5B). Overall, this pattern
suggests that the unique response of CEBPs and their target genes is most consistently
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Figure 4.5: Increase of CEBP mRNA and CEBP targets in PBMCs is a unique response to
Filovirus infection. Barcharts depicting the average expression during different viral infections of (A)
two house-keeping genes (ACTB and GAPDH), two interferon-stimulated genes (ISG15 and OAS1), and
two CEBP genes (CEBPB and CEBPE); and, (B) three “gold standard” CEBP-responsive genes (HP,
LCN2 and PTX3). Bars indicate the expression, averaged across probes and samples (y-axis) for several
different viral infections (x-axis); error bars reflect the standard error. Dashed grey line indicates a log2
fold-change of 2, the typical cutoff for significance. Scale is log2 fold-change calculated from pre-infection
levels. All samples were averaged across symptomatic stages of infection for all viral families. Bars are
colored according to viral family, legend is indicated on the bottom.
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associated with Filovirus infection.
4.4.5 Up-regulation of CEBP-responsive genes is not a signature of acute
phase response
I observed that several CEBP-responsive genes, such as C3, HGF, HP, LCN2, LPL, and
PTX3 [64, 72, 89, 136, 172, 179], are associated with acute phase response, the process in
which the concentration of certain proteins rapidly increases or decreases following infec-
tion. Previous research has also suggested that the acute phase response is activated in
murine models of Ebola virus infection [26, 98]. I was interested in determining whether
there was a clear signature of acute phase response in PBMCs in response to Filovirus in-
fection. I examined a set of common positive acute phase proteins, which are expected to
become significantly up-regulated in response to infection: ceruloplasmin (CP), C-reactive
protein (CRP), ferritin (FTL), hepcidin (HAMP), orosomucoid 1 (ORM1), and serum
amyloid A 1 (SAA1). I also examined the expression of a negative acute phase protein,
transferrin (TF), which is expected to significantly decrease following activation of acute
phase response following infection [154].
When I compared the average log2-fold change of acute phase response genes on Day
7 post-infection, the expression of most acute phase response genes was not significantly
different (Figure 4.6). Following EBOV infection, I observed up-regulation of FTL (2.8 log2-
fold), CP (1.6 log2-fold) and SAA1 (1.6 log2-fold; Figure 4.6A). In general, the up-regulation
of acute phase response genes following EBOV infection was restricted to the CEBP-
responsive genes (Figure 4.6A). Similarly, there was little to no differential expression of
most acute phase response genes following MARV infection, with the exception of SAA1
(Figure 4.6B). The magnitude of up-regulation of SAA1 was similar to the magnitude of up-
regulation of CEBP-responsive genes following MARV infection (5.1 log2-fold); in contrast,
the remaining acute phase response genes were not up-regulated (Figure 4.6B). This pattern
of expression suggests that there is no obvious signature of acute phase response in PBMCs
following Filovirus infection.
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Figure 4.6: Up-regulation of CEBP-responsive genes is not a signature of acute phase re-
sponse. Barcharts depicting the average expression of acute phase response genes, compared to the set of
“gold standard” CEBP-responsive genes following (A) EBOV infection; and (B) MARV infection. Bars
indicate the expression, averaged across probes and samples (y-axis), of several different genes (x-axis) on
Day 7 post-infection. Error bars reflect the standard error. Dashed grey line indicates a log2 fold-change
of 2, the typical cutoff for significance. Scale is log2 fold-change calculated from pre-infection levels. Bars
are colored according to gene set: acute phase response (CP, CRP, FTL, HAMP, ORM1, SAA1, and TF),
and “gold standard” CEBP-responsive genes(HP, LCN2 and PTX3). Legend is indicated at the top left.
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4.4.6 Genes associated with iron metabolism are up-regulated in Filovirus
infection
In my examination of acute phase response, I observed that some acute phase response
genes, such as CP and FTL, are also known to regulate iron metabolism [10, 155]. In
addition, several CEBP-responsive genes are also associated with iron metabolism, such
as DCN, HGF, HP, LCN2, and LPL [30, 69, 86, 91, 101, 140, 143]. I was interested in
determining whether there was a clear signature of iron metabolism in PBMCs in response
to Filovirus infection. I examined the expression of 8 genes commonly associated with
iron metabolism according to the literature [10, 198], but which were not associated with
acute phase response: F-box/LRR-repeat protein 5 (FBXL5); hypoxia-inducible factor 1-α
(HIF1A); heme oxygenase 1 (HMOX1); hemopexin (HPX); lactoferrin (LTF); solute carrier
family 25 (mitochondrial iron transporter), member 37 (SLC25A37); superoxide dismutase
2, mitochondrial (SOD2); and, STEAP family member 4 (STEAP4). I compared the
expression of these genes following EBOV infection and MARV infection, to the expression
of HP, LCN2 and PTX3, of which HP and LCN2 are also known to bind iron [91].
I examined the average log2 fold-change of these iron metabolism genes on Day 7
post-infection of EBOV or MARV (Figure 4.7). In general, I observed that the major-
ity of the iron metabolism genes (6 out of 8 genes, 75%) became up-regulated following
EBOV infection (Figure 4.7A). In particular, I observed high up-regulation of such as
FBXL5 (2.4 log2-fold), HMOX1 (3.6 log2-fold), SLC25A37 (2.6 log2-fold), and SOD2 (3.9
log2-fold), and marginal up-regulation of LTF (2.1 log2-fold), and STEAP4 (2.4 log2-fold;
Figure 4.7A). I observed a similar trend of up-regulation in PBMCs following MARV infec-
tion (Figure 4.7B). In general, the magnitude of up-regulation observed following EBOV
infection and MARV infection was not as significant as the magnitude of up-regulation of
HP, LCN2 and PTX3. However, this pattern of expression suggests that genes regulating
iron metabolism may become up-regulated in PBMCs following Filovirus infection. Indeed,
I observed up-regulation of ferritin (FTL) following EBOV infection (Figure 4.6A), similar
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to the observations reported in clinical samples of humans infected by Sudan Ebola virus
[126].
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Figure 4.7: Genes associated with iron metabolism are up-regulated in Filovirus infection.
Barcharts depicting the average expression of iron metabolism genes, compared to the set of “gold stan-
dard” CEBP-responsive genes following (A) EBOV infection; and (B) MARV infection. Bars indicate
the expression, averaged across probes and samples (y-axis), of several different genes (x-axis) on Day 7
post-infection. Error bars reflect the standard error. Dashed grey line indicates a log2 fold-change of 2, the
typical cutoff for significance. Scale is log2 fold-change calculated from pre-infection levels. Bars are colored
according to gene set: iron metabolism (CP, FBXL5, FTL, HIF1A, HMOX1, HPX, LTF, SLC25A37, and
SOD2, STEAP4), and “gold standard” CEBP-responsive genes (HP, LCN2 and PTX3). Legend is indicated
at the top left.
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4.4.7 Genes associated with low-density granulocytes (LDGs) are up-regulated
in Filovirus infection
In addition to being associated with acute phase response and iron metabolism, several
CEBP-responsive genes are associated with neutrophils and granulocyte differentiation,
such as FOS, HGF, HP, LCN2, PTX3 and S100A8 [71, 103, 105, 159, 183, 212]. Although
I did not expect to observe a signature of neutrophil activity within PBMCs, I hypothesize
that a signature of low-density granulocyte (LDG) activity could be present in this dataset.
I was interested in determining whether there was a signature of LDG activity in PBMCs
following Filovirus infection. To identify a set of genes which were specific to neutrophils,
I probed the Immunological Genome Project database (ImmGen, [80]) using the Gene
Skyline application. I identified 7 genes which were highly expressed in neutrophils from
bone marrow, but not differentially expressed in other immune cell types: ankyrin repeat
domain 22 (ANKRD22), arginase 2 (ARG2), chitinase-3-like protein 1 (CHI3L1), formyl
peptide receptor 1 (FPR1), interleukin-1 family member 9 (IL1F9), maltase-glucoamylase
(MGAM), and matrix metalloproteinase-8 (MMP8). In addition, CEBPD, CEBPE, LTF
and ORM1 were highly expressed in neutrophils when compared to other cell types [80], but
are not included in Figure 4.8, due to the fact that they are illustrated in previous figures
(Figure 4.2, Figure 4.6, Figure 4.7). I compared the expression of these neutrophil-specific
genes following EBOV and MARV infection, to the expression of “gold standard” CEBP-
responsive genes such as HP, LCN2 and PTX3, which are all associated with neutrophil
differentiation.
I compared the average log2 fold-change of LDG-associated genes on Day 7 post-
infection of EBOV or MARV (Figure 4.8). I observe up-regulation of ARG2 (4.1 log2-
fold), FPR1 (3.3 log2-fold), MGAM (2.9 log2-fold), and MMP8 (8.2 log2-fold) following
EBOV infection, suggesting that there is a signature of LDGs in the PBMC fraction of
this dataset (Figure 4.8A). Similarly, following MARV infection I observed up-regulation of
ANKRD22 (5.9 log2-fold), ARG2 (2.7 log2-fold), FPR1 (3.2 log2-fold), MGAM (3.5 log2-
83
A
ANKRD22 LCN2 PTX3
 ∆
 F
o
ld
 C
h
an
g
e;
 L
o
g
2
 S
ca
le
Low-Density Granulocyte Gene Expression on Day 7 Post-Infection of EBOV
 CEBP-Responsive Genes
 Low-Density Granulocyte Genes
0
2
4
6
8
ARG2 CHI3L1 FPR1 IL1F9 LTF MGAM MMP8 ORM1 HP
B
ANKRD22 LCN2 PTX3
 ∆
 F
o
ld
 C
h
an
g
e;
 L
o
g
2
 S
ca
le
Low-Density Granulocyte Gene Expression on Day 7 Post-Infection of MARV
 CEBP-Responsive Genes
 Low-Density Granulocyte Genes
0
2
4
6
8
ARG2 CHI3L1 FPR1 IL1F9 LTF MGAM MMP8 ORM1 HP
Figure 4.8: Genes associated with low density granulocytes (LDGs) are up-regulated in
Filovirus infection. Barcharts depicting the average expression of low-density granulocyte (LDG)-
associated genes, compared to the set of “gold standard” CEBP-responsive genes following (A) EBOV
infection; and (B) MARV infection. Bars indicate the expression, averaged across probes and samples
(y-axis), of several different genes (x-axis) on Day 7 post-infection. Error bars reflect the standard er-
ror. Dashed grey line indicates a log2 fold-change of 2, the typical cutoff for significance. Scale is log2
fold-change calculated from pre-infection levels. Bars are colored according to gene set: LDG-associated
genes (ANKRD22, ARG2, CHI3L1, FPR1, IL1F9, LTF, MGAM, MMP8, and ORM1), and “gold standard”
CEBP-responsive genes (HP, LCN2 and PTX3). Legend is indicated at the top left.
fold), and MMP8 (6.4 log2-fold; Figure 4.8B). Overall, the magnitude of up-regulation
observed in LDG-associated genes was not as high as the magnitude of up-regulation
in CEBP-responsive genes such as HP, LCN2 and PTX3. However, MMP8 was highly
up-regulated following both EBOV and MARV infection, and ANKRD22 was highly up-
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regulated following MARV infection. This is consistent with neutrophil populations being
present in the PBMC fraction, suggesting that there is a presence of immature neutrophils
or LDGs in the PBMCs.
4.5 Discussion
This analysis suggests that the CEBP protein family merits further study in the context
of Filovirus infection. Previously, I have demonstrated that CEBPA is associated with a
profile of survival following anticoagulant-treatment of NHPs infected with EBOV (Chap-
ter 3). Although CEBPA itself was not differentially regulated, the expression pattern of
CEBPA-regulated genes suggested that CEBPA activity was down-regulated or inhibited
in NHPs which survived EBOV infection, compared to non-survivors. In this study, I have
demonstrated that knocking down CEBPA using a shRNA model will inhibit EBOV growth
in A549 cells. Using data from a zinc-inducible expression vector study [63], I observed
that CEBP-regulated genes were the most up-regulated in response to CEBPA induction,
and were less up-regulated in response to induction of other CEBPs (Figure 4.2A). Overall,
these results suggest that inhibiting CEBPA activity may mitigate the severe dysregulation
of host immune response to EBOV infection, in addition to potentially preventing EBOV
replication.
CEBPs have numerous roles in the host immune response [3, 112, 113, 114, 145, 207].
Notably, I observed that several CEBP-regulated genes are also associated with acute phase
response [64, 72, 89, 136, 172, 179]. However, acute phase proteins are typically produced
by the liver and measured as soluble protein in serum, therefore I did not expect to observe
changes in these biomarkers to be detected in circulating PBMCs. Nevertheless, I observed
up-regulation of some acute phase proteins following CEBP up-regulation, although I did
not see a total recapitulation of the acute phase response. This suggests that the observed
up-regulation is not due exclusively to acute phase response, but rather it is a signature
of CEBP up-regulation which may, in turn, activate and up-regulate some acute phase
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proteins.
I also observed that several CEBP-regulated genes are associated with iron metabolism
[30, 69, 86, 91, 101, 140, 143]. Several other acute phase proteins produced by the liver are
associated with iron metabolism, suggesting that maintaining iron homeostasis is a critical
part of the innate immune response to infection [89, 91, 172]. Iron metabolism has become a
recurring factor in the study of Filovirus infections. For example, a recent study found that
increased levels of ferritin were correlated with increased morbidity and mortality in humans
infected with Sudan Ebola virus (SUDV) [126]. In addition, in a previous study I found
that decreased transcription of lactoferrin, another iron-binding protein, was associated
with increased survival in anticoagulant-treated EBOV-infected NHPs (Chapter 3). In
this study of fatal EBOV infection of NHPs, I observed up-regulation of CEBP-regulated
genes such as HP and LCN2, which both sequester iron [30, 86, 91]. In addition, I observed
up-regulation of other iron metabolism-associated genes which are not CEBP-regulated,
such as HMOX1, SOD2 and STEAP4. These results suggest that iron metabolism may
play a role in regulating host response to Filovirus infection, and that CEBPs may play a
role in maintaining homeostasis of iron metabolism during infection.
Additionally, CEBPs are known to be expressed by neutrophils, and are known to
be associated with granulocyte differentiation [16, 113, 114, 131, 212]. Several CEBP-
regulated genes are also produced by neutrophils [71, 103, 105, 159, 183, 212], suggesting
that part of the transcriptional response I observed in PBMCs may come from a unique
class of neutrophils, called low-density granulocytes (LDGs), which have been implicated
in other viral infections [27]. Indeed, I observed up-regulation of many LDG-specific genes,
such as ARG2 and MMP8, which are not regulated by CEBPs and are not produced by
other cells in the PBMC population. These results strongly suggest that transcriptional
profile in which CEBPs and their down-stream targets become up-regulated, may originate
from a population of LDGs within PBMCs. In addition, a recent study found that Filovirus
infection of human neutrophils in vitro can activate a class of innate receptors called trigger
receptor expressed in myeloid cells (TREM) receptors [129]. These findings suggest a
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possible role for this unique class of neutrophils in Filovirus infection, as mediators of early
immune response.
These results collectively suggest that CEBPs, iron metabolism, and neutrophil ac-
tivation are associated with Filovirus infection. I propose a model in which Filovirus
infection leads to the dysregulation of normal neutrophil activity (Figure 4.9), perhaps by
activating innate receptors, as reported in a previous study [129]. In particular, LDGs
are known to trigger severe innate immune responses, and are characterized by an in-
creased pro-inflammatory response, decreased phagocytic ability, and an increased capac-
ity to form neutrophil extracellular traps (NETs), which are known to cause endothelial
damage [22, 191]. Increase in the mRNA of CEBPs could be due to either up-regulation of
these genes, or the addition of new mRNA due to infiltration of neutrophils into the PBMC
fraction, adding a new pool of previously unavailable mRNA. It is unclear whether LDG
activity causes an increase in CEBP mRNA, or whether increasing CEBP mRNA causes an
increase in LDG activity; or, whether there is a third, unrelated event causing simultaneous
increases in both. I hypothesize that the increase in CEBP mRNA causes up-regulation of
other innate immune response genes and genes which regulate iron metabolism. Dysreg-
ulation of iron metabolism can lead to oxidative intravascular damage and liver damage,
leading to coagulopathies and hemorrhage [9, 195], which are common symptoms of late-
stage EVD [56, 82]. I additionally hypothesize that EBOV infection requires high levels
of CEBPA to promote viral replication, which could be fulfilled by LDG activity, which
causes up-regulation of CEBPs. Overall, these findings support the hypothesis that CEBPs
play a unique role in the pathogenesis and outcome of Filovirus infection, and that iron
metabolism and LDG activity are crucial to understanding the role of CEBPs in Filovirus
infection.
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Figure 4.9: A model of the role of CEBPs in Filovirus infection. This cartoon model illustrates
the role we hypothesize that CEBPs, low-density granulocytes, and iron metabolism have in Filovirus
infection. Red arrows indicate activation of regulation, which is illustrated as up-regulation of CEBPs
through unknown factors, or up-regulation of CEBP-responsive genes through the activity of CEBPs.
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Chapter 5
Conclusions & Future Directions
5.1 Summary of dissertation work
In this dissertation, I focused on two broad questions associated with host-virus interaction
systems: (1) how do viruses interact with their hosts? and, (2) what are the downstream
consequences of specific host-virus interactions, as observed within the host? To address the
first question, I completed a global, quantitative assessment of human-virus protein-protein
interaction networks. I compared the qualities of this network to the typical human-human
protein-protein interaction network, to determine in what ways human-virus interactions
differ from human-human interactions. To address the second question, I completed two
studies of the host immune response of non-human primates to Ebola virus or similar viral
hemorrhagic fevers. In the first study, I used microarray analysis and pathway analysis to
identify transcriptional correlates of survival following anticoagulant treatment of Ebola
virus-infected non-human primates, and to identify upstream transcriptional regulators
which control these survival-associated profiles. In the second study, I extended my results
to other viral hemorrhagic fevers, such as the related Marburg virus, to examine the role
of a specific family of transcription factors during Filovirus infection. I identified a unique
signature associated with this family of transcription factors, which has not previously
been associated with Filovirus infection.
5.2 Significance of host-virus interaction studies
In Chapter 2, I explored the mechanisms of interaction between virus proteins and human
proteins. I improved upon previous host-virus protein-protein interaction (PPI) networks
by using domain-resolved annotations of proteins and interactions. The typical approach
to studying host-pathogen PPI networks yields a network which is binary and lacks high
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resolution, treating proteins as nodes and PPIs as edges. In contrast, previous work which
integrated 3D structural models will increase the information about the interaction, at
the cost of significantly reducing the scope of the network. My approach of using domain-
resolved annotations resulted in a high-coverage, high-resolution human-virus PPI network,
which maintained the scope of binary networks, but provided more information about the
mechanism of interaction taking place between two proteins. By classifying interactions as
domain-domain interactions (DDIs) and domain-motif interactions (DMIs), I could com-
pare and contrast the differences between human-human PPIs and human-virus PPIs.
My analyses revealed trends which differentiate human-virus interactions from human-
human interactions. These results were the first to quantify the differences between exoge-
nous and endogenous interactions in the context of a domain-resolved, high-covered PPI
network. My findings demonstrated that viral proteins preferentially choose strategies that
maximize the effectiveness of their interactions with the host, and consequently host-virus
interactions exhibit properties of pleiotropy. For example, viral proteins have a propensity
for using linear motifs and linear motif-binding domains to mediate interactions; these
results suggest that linear motifs could be targeted for therapeutics. One way to inhibit
host-virus interactions is for small molecules to competitively bind host proteins; short
linear motifs can provide a wide array of these small molecules to explore as competitive
binding agents which can inhibit host-virus interactions [95]. Ideally, manufactured lin-
ear motifs could target the common domains mediating host-virus interactions exclusively.
Alternatively, for those viruses that contain larger globular domains in their proteins, man-
ufactured linear motifs could be used to bind the viral proteins instead of host proteins; for
example, competitive binding by small molecules to viral glycoproteins could inhibit viral
entry into the cell. Finally, this study also demonstrated the utility of combining domain-
resolved annotations with binary PPI networks, for the purpose of elucidating mechanisms
of interaction between two organisms. Although my findings were limited in scope to the
viruses represented in the study, the methodology is applicable and extendable to other
networks.
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My study of the human-virus PPI network revealed unique mechanisms of interaction
which differentiated human-virus interactions from human-human interactions. However,
due to the exponential nature of data generation in the field of bioinformatics, the den-
sity and complexity of the human-virus interactome will rapidly increase as new PPIs and
domain-resolved annotations become available. Therefore, the methodology of this study
could be easily re-applied to new datasets in order to further elucidate the mechanisms
that describe human-virus PPIs. In addition, this approach could be applied to other
studies of host-pathogen interaction networks, especially if the pathogen is an intracellular
parasite and is known to have physical interactions with human proteins. Identifying the
mechanisms by which these pathogens can interact with host proteins can be useful for
identifying druggable targets, or guiding studies of diagnostics or therapeutics. Another
possible application is to study the interactions between the proteins of humans and bac-
teria in the gut microbiome, in order to better understand how gut microflora effect the
human interactome. As the cost of high-throughput PPI experimental technology contin-
ues to fall, and as predictions of computationally-derived PPIs continues to improve, more
datasets will become available for analysis. Until better predictions or more datasets are
available, using domain-resolved annotation information is useful for understanding the
mechanisms that govern complex interactions within and between species. These analyses
are applicable not only to further the general understanding of how a virus interacts with
its host, but these approaches can also be useful for identifying druggable targets to prevent
host-virus interactions.
5.3 Significance of host transcriptional response to Ebola virus
In Chapter 3, I evaluated the gene expression in circulating immune cells from anticoagulant-
treated non-human primates (NHPs) infected with Ebola virus (EBOV). I improved upon
previous studies of host immune response to EBOV by using advance microarray analysis
techniques and by comparing surviving NHPs to non-surviving NHPs. There have been
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several studies which have evaluated the efficacy of therapeutic treatments in NHPs infected
with EBOV [47, 55, 58, 59, 60, 83, 92, 152, 178]; however, these studies typically evaluate
individual genes and proteins, and therefore are limited to available biological assays. In
contrast, I used high-throughput cDNA microarray analysis in order to evaluate the global
transcriptional response of circulating immune cells to EBOV infection, thereby increasing
coverage of the transcriptome. This approach allowed me to identify early transcriptional
markers of immune response, prior to the appearance of clinical symptoms. Previously,
a study used microarray analysis to evaluate EBOV-infected NHPs [158]; however, this
study did not include anticoagulant treatment and therefore could not assess correlates of
survival. In previously published work, I assessed the response of anticoagulant-treated
NHPs to EBOV infection, but limited the scope to treatment-associated profiles [208]. In
this previous study, I did not thoroughly explore survival-associated profiles, and did not
identify transcriptional regulators of gene expression.
My approach of combining pathway analysis with microarray analysis revealed novel
transcriptional patterns which are associated with survival following anticoagulant treat-
ment in EBOV-infected NHPs. My results were the first to identify a gene set which can
quantitatively and statistically differentiate disease outcomes (e.g. survival, non-survival)
following EBOV infection in NHPs. This study demonstrated the utility of combining
microarray analysis with pathway analysis and statistically rigorous tests, for the purpose
of identifying statistically significant regulators of transcriptional profiles correlated with
survival. Although my conclusions were limited in scope to the context of anticoagulant-
treated EBOV-infected NHPs, these approaches are applicable and extendable to other
transcriptomic analyses. For example, it would be interesting to evaluate the transcriptome
of EBOV-infected NHPs which have received a trial vaccine against EBOV, to determine
how vaccination changes the host immune response, and which transcriptional changes
correlate with successful immunization.
In addition, my analysis identified several transcription factors as being associated with
survival, such as CEBPA, P53 and MKL1/MKL2. Although some of these genes have been
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previously associated with other viral infections [133, 175, 186], they need to be studied
in the context of EBOV infection to understand their roles, if any, in the host immune
response to EBOV, preferably in an in vivo experimental setting. In particular, these
correlated transcription factors–CEBPA, P53, MKL1 and MKL2–can be further studied
as possible diagnostic sources. I identified several individual gene products, such as LTF
and MIR-122, which are correlated with survival and are promising candidates for study.
MIR-122 is a microRNA which has been previously associated with Hepatitis C replication
[93, 94]; although no studies have linked MIR-122 to EBOV, several binding sites for MIR-
122 exist in the EBOV genome, suggesting that this microRNA may be associated with
EBOV replication. Similarly, LTF has not been linked to EBOV infection, although a
study of clinical samples from humans infected with Sudan Ebola virus identified a related
iron-transport protein, FTL, as being correlated with morbidity and mortality [126]. It is
clear that iron metabolism has some role to play in EBOV infection, but further studies
need to be done in order to determine the exact mechanism of action.
5.4 Significance of the role of CEBPs in Filovirus infection
In Chapter 4, I extended my previous findings in Chapter 3 and thoroughly investigated
the role that CCAAT-enhancer-binding proteins (CEBPs) have in Filovirus infection. I uti-
lized comparative microarray analysis of several different, previously published datasets,
to identify signatures of CEBP-activity that are unique to Filovirus infection. Previous
studies have used transcriptomics to identify unique signatures of different viral infections
[88, 204, 210]; however, this was the first study to use this approach for viral hemorrhagic
fevers. In addition, this was the first microarray study to contrast Filovirus infection to
other hemorrhagic fevers such as Lassa virus and Dengue virus, and to non-hemorrhagic
infections such as Influenza virus and Lymphocytic choriomeningitis virus. Additionally, I
used independently published and curated datasets to identify specific gene sets, such as
those associated with low-density granulocyte activity, in order to evaluate specific tran-
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scriptional profiles, instead of just evaluating gene expression in a de novo, ”gold mining”
approach. My approach of using comparative microarray analysis of several different viral
infections in humans and NHPs can easily be extended to additional work. In this work I
only compared Filovirus infection to a small group of viral infections, such as hemorrhagic
Arenaviruses (Lassa, Lymphocytic choriomeningitis virus) and Flaviviruses (Dengue), as
well as non-hemorrhagic respiratory viruses (Influenza). One possible application is to
extend the study to chronic infections; there are many microarray datasets available eval-
uating the host immune response to chronic viral infections such as HIV, hepatitis C, or
herpesvirus-induced chronic diseases.
My analyses of CEBPs and related genes suggested a unique profile of regulation that
was associated with Filovirus infection, and not with other viral infections. My results
demonstrated a relationship between CEBPs and Filovirus infection which was not reca-
pitulated completely in other viral infections, including viral hemorrhagic fever infections.
However, a significant amount of research remains to be done to identify how CEBPs effect
EBOV replication, and how changes in the host immune response can promote pathogene-
sis. Future experimental studies could evaluate CEBP activity in Filovirus infection using
protein assays or genetic studies, such as additional knock-down or knock-out studies, to ac-
curately determine the transcriptional and translational behavior of CEBPs over the course
of Filovirus infection. I also determined that CEBP responsive genes are differentially ex-
pressed in Filovirus infection and some other viral infections which cause hemorrhagic fever
in humans and non-human primates. Future studies could evaluate the expression of these
genes in a wider array of datasets, to determine whether these genes are truly associated
with viral hemorrhagic fever.
My findings were also the first to demonstrate transcriptional profiles relating CEBPs
to genes associated with iron metabolism and low-density granulocytes. Although previous
work has also suggested that genes related to iron metabolism may be associated with mor-
bidity and mortality of Ebola virus infection in humans [126], this study was the first to
use a transcriptomic approach to evaluate iron metabolism in the context of EBOV infec-
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tion. These genes associated with iron metabolism merit further study using experimental
approaches–such as gene knock-down experiments or protein assays–to more accurately
determine their role in Filovirus infection. In particular, it is important to consider using
gene or protein assays that are able to evaluate iron metabolism when conducting a low-
throughput study of EBOV infection. There are already several assays available against
common regulators of iron, such as hepcidin and serum ferritin, which could easily be
incorporated into existing protocols for evaluating NHP response to Filovirus infection.
Similarly, previous studies have linked neutrophils to other viral infections, including
Ebola virus [27, 129]; however, this was the first study to demonstrate a transcriptional
signature of low-density neutrophils following Ebola virus infection. I revealed signatures
of neutrophil activity following Filovirus infection, as demonstrated by the significant up-
regulation of genes which are expressed uniquely in circulating neutrophils. This implies
an additional component of neutrophils in the peripheral blood mononuclear cell (PBMC)
fraction, which is most realistically accomplished by the presence of low-density granulo-
cytes, which have similar density to PBMCs. Although neutrophils have been associated
with Filovirus infection, this is the first study to evaluate their contribution to the immune
cell transcriptome following NHP infection by Filoviruses. Further experiments need to
be done in order to determine whether the population of neutrophil-like cells is truly low-
density granulocytes, perhaps by doing experimental studies to evaluate cell morphology
in PBMC samples.
It will also be important to determine when these low-density granulocytes appear in
the PBMC fraction of circulating immune cells, and how they change over time. Stud-
ies utilizing cell separation could determine if the signatures of CEBPs and other related
genes were uniquely occurring in low-density granulocytes, or whether it was an overall im-
mune response also present in other PBMC cell types. Further analysis would be required
to accurately determine whether low-density granulocytes are driving gene expression, or
whether they are simply one component of a greater immune response. Finally, low-density
granulocytes merit further study as a signature of late stage Filovirus infection, and espe-
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cially as a potential diagnostic of disease outcome. In particular, it is important to confirm
that accumulation of low-density granulocytes is a signature of increased morbidity and
mortality; therefore, assays evaluating low-density granulocyte presence following Filovirus
infection could provide a metric to determine prognosis.
Although my conclusions are limited in scope to the context of these datasets, these
results strongly suggest a relationship between Filovirus infection and CEBPs, low density
neutrophils, and possibly iron metabolism. These results could directly be applicable in
the future development of diagnostics, such as small, portable protein assays, especially for
predicting disease outcome following Filovirus infection.
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Appendix A
Supplemental Figures
A.1 Cartoon representation of Materials and Methods
Figure A.1: Cartoon representation of Materials and Methods. This figure illustrates the overall
process of microarray analysis described in this paper, including sample collection, microarray processing
and normalization, and analysis of the data (as described in Section 3.3).
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Appendix B
Supplemental Tables
B.1 Number of proteins and interactions per viral family
ICTV Family Number of Unique Proteins Total Interactions
Adenoviridae 25 68
Arenaviridae 4 5
Circoviridae 1 1
Coronaviridae 2 3
Filoviridae 1 1
Flaviviridae 16 62
Hepadnaviridae 4 19
Hepeviridae 2 3
Herpesviridae 72 359
Orthomyxoviridae 21 222
Papillomaviridae 44 253
Paramyxoviridae 3 4
Picornaviridae 3 4
Polyomaviridae 9 52
Poxviridae 10 29
Reoviridae 2 3
Retroviridae 48 582
Exogenous 267 1,670
Endogenous 9,870 39,329
Table B.1: This table lists the number of unique proteins and total number of interactions reported for
each viral family found in the network, as annotated by the 2011 release of the International Committee
on Taxonomy of Viruses.
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B.2 Human domains observed in viral proteins
Human domain in
virus protein (Pfam)
Virus protein
(Uniprot)
Target domain (Pfam) in human
protein (Uniprot)
7tm 1 Q777B2 LRRNT (O94813)
Cyclin N Q01043 Pkinase (Q00534)
DNA pol B P03261 Pkinase (P06493)
DnaJ P03070 AAA (P62195); Pkinase (O43683,
P06493, P24941, P68400); Ras
(P62826); Rb C (P06400); WD40
(O43684, Q969H0, Q9UKB1, Q9Y297)
dsrm P21605 dsrm (P19525); Pkinase (P19525)
Helicase C P14340 Pkinase (Q9UHY1)
IL10 P03180, P17150 Interfer-bind (Q13651); Tissue fac
(Q13651)
IL6 Q98823 fn3 (P40189); IL6Ra-bind (P40189)
K-cyclin vir C Q01043 Pkinase (Q00534)
Pkinase
P0C731 IQ (Q13576); RasGAP (Q13576)
P20505 bZIP 1 (P05412); Jun (P05412); Pkinase
(O14733); SH3 1 (Q9UQF2)
Pkinase Tyr P15054 C1 1 (P04049); Pkinase Tyr (P04049);
RBD (P04049); SH3 1 (Q9NZQ3)
S1 P20639 Pkinase (P19525)
Sema Q8JL80 PSI (O60486); TIG (O60486)
SH2
P00524 KH 1 (Q07666)
P15054 C1 1 (P04049); Pkinase Tyr (P04049);
RBD (P04049); SH3 1 (Q9NZQ3)
SH3 1
P00524 Metallophos (P67775)
P15054 C1 1 (P04049); Pkinase Tyr (P04049);
SH3 1 (Q9NZQ3)
TNFR c6 Q8V2D1 MATH (Q9Y4K3); zf-TRAF (Q9Y4K3)
z-alpha P21605 dsrm (P19525)
Table B.2: This table lists the 17 unique human domains that are observed in viral proteins to mediate
30 domain-domain interactions with human proteins.
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